<!DOCTYPE html>
<html lang="en" dir="ltr" class="client-nojs">
<head>
<meta charset="UTF-8" />
<title>Hairy cell leukemia - Wikipedia, the free encyclopedia</title>
<meta name="generator" content="MediaWiki 1.26wmf13" />
<link rel="alternate" href="android-app://org.wikipedia/http/en.m.wikipedia.org/wiki/Hairy_cell_leukemia" />
<link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Hairy_cell_leukemia&amp;action=edit" />
<link rel="edit" title="Edit this page" href="/w/index.php?title=Hairy_cell_leukemia&amp;action=edit" />
<link rel="apple-touch-icon" href="/static/apple-touch/wikipedia.png" />
<link rel="shortcut icon" href="/static/favicon/wikipedia.ico" />
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (en)" />
<link rel="EditURI" type="application/rsd+xml" href="//en.wikipedia.org/w/api.php?action=rsd" />
<link rel="alternate" hreflang="x-default" href="/wiki/Hairy_cell_leukemia" />
<link rel="copyright" href="//creativecommons.org/licenses/by-sa/3.0/" />
<link rel="alternate" type="application/atom+xml" title="Wikipedia Atom feed" href="/w/index.php?title=Special:RecentChanges&amp;feed=atom" />
<link rel="canonical" href="https://en.wikipedia.org/wiki/Hairy_cell_leukemia" />
<link rel="stylesheet" href="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=ext.uls.nojs%7Cext.visualEditor.viewPageTarget.noscript%7Cext.wikihiero%7Cmediawiki.legacy.commonPrint%2Cshared%7Cmediawiki.sectionAnchor%7Cmediawiki.skinning.interface%7Cmediawiki.ui.button%7Cskins.vector.styles%7Cwikibase.client.init&amp;only=styles&amp;skin=vector&amp;*" />
<meta name="ResourceLoaderDynamicStyles" content="" />
<link rel="stylesheet" href="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=site&amp;only=styles&amp;skin=vector&amp;*" />
<style>a:lang(ar),a:lang(kk-arab),a:lang(mzn),a:lang(ps),a:lang(ur){text-decoration:none}
/* cache key: global:resourceloader:filter:minify-css:7:de1ab5287c9076b96eedd3f97a84a7b6 */</style>
<script src="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=startup&amp;only=scripts&amp;skin=vector&amp;*"></script>
<script>if(window.mw){
mw.config.set({"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":false,"wgNamespaceNumber":0,"wgPageName":"Hairy_cell_leukemia","wgTitle":"Hairy cell leukemia","wgCurRevisionId":665127407,"wgRevisionId":665127407,"wgArticleId":1094648,"wgIsArticle":true,"wgIsRedirect":false,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Pages with DOIs inactive since 2015","CS1 Japanese-language sources (ja)","Articles with contributors link","Articles that use a Medicine navs subtemplate","Lymphocytic leukemia","Lymphoid-related cutaneous conditions"],"wgBreakFrames":false,"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"dmy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgMonthNamesShort":["","Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec"],"wgRelevantPageName":"Hairy_cell_leukemia","wgRelevantArticleId":1094648,"wgIsProbablyEditable":true,"wgRestrictionEdit":[],"wgRestrictionMove":[],"wgMediaViewerOnClick":true,"wgMediaViewerEnabledByDefault":true,"wikilove-recipient":"","wikilove-anon":0,"wgPoweredByHHVM":true,"wgWikiEditorEnabledModules":{"toolbar":true,"dialogs":true,"hidesig":true,"preview":false,"publish":false},"wgBetaFeaturesFeatures":[],"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","usePageImages":true,"usePageDescriptions":true},"wgGatherShouldShowTutorial":true,"wgGatherPageImageThumbnail":"//upload.wikimedia.org/wikipedia/commons/thumb/9/91/Hairy_cell_leukemia.jpg/100px-Hairy_cell_leukemia.jpg","wgULSAcceptLanguageList":["en-us","en"],"wgULSCurrentAutonym":"English","wgFlaggedRevsParams":{"tags":{"status":{"levels":1,"quality":2,"pristine":3}}},"wgStableRevisionId":null,"wgCategoryTreePageCategoryOptions":"{\"mode\":0,\"hideprefix\":20,\"showcount\":true,\"namespaces\":false}","wgNoticeProject":"wikipedia","wgWikibaseItemId":"Q201299"});
}</script><script>if(window.mw){
mw.loader.implement("user.options",function($,jQuery){mw.user.options.set({"variant":"en"});});
/* cache key: global:resourceloader:filter:minify-js:7:b2706269305541eba923c165462b22c4 */
}</script>
<script>if(window.mw){
mw.loader.implement("user.tokens",function($,jQuery){mw.user.tokens.set({"editToken":"+\\","patrolToken":"+\\","watchToken":"+\\"});});
}</script>
<script>if(window.mw){
mw.loader.load(["mediawiki.page.startup","mediawiki.legacy.wikibits","mediawiki.legacy.ajax","ext.centralauth.centralautologin","mmv.head","ext.imageMetrics.head","ext.visualEditor.viewPageTarget.init","ext.uls.init","ext.uls.interface","ext.centralNotice.bannerController","skins.vector.js"]);
}</script>
<link rel="dns-prefetch" href="//meta.wikimedia.org" />
<!--[if lt IE 7]><style type="text/css">body{behavior:url("/w/static/1.26wmf13/skins/Vector/csshover.min.htc")}</style><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Hairy_cell_leukemia skin-vector action-view">
		<div id="mw-page-base" class="noprint"></div>
		<div id="mw-head-base" class="noprint"></div>
		<div id="content" class="mw-body" role="main">
			<a id="top"></a>

							<div id="siteNotice"><!-- CentralNotice --></div>
						<div class="mw-indicators">
</div>
			<h1 id="firstHeading" class="firstHeading" lang="en">Hairy cell leukemia</h1>
									<div id="bodyContent" class="mw-body-content">
									<div id="siteSub">From Wikipedia, the free encyclopedia</div>
								<div id="contentSub"></div>
												<div id="jump-to-nav" class="mw-jump">
					Jump to:					<a href="#mw-head">navigation</a>, 					<a href="#p-search">search</a>
				</div>
				<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><table class="infobox" style="width:22em">
<tr>
<th colspan="2" style="text-align:center;font-size:125%;font-weight:bold;background-color: lightgrey">Hairy cell leukemia</th>
</tr>
<tr>
<td colspan="2" style="text-align:center"><a href="/wiki/File:Hairy_cell_leukemia.jpg" class="image"><img alt="Hairy cell leukemia.jpg" src="//upload.wikimedia.org/wikipedia/commons/thumb/9/91/Hairy_cell_leukemia.jpg/230px-Hairy_cell_leukemia.jpg" width="230" height="157" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/9/91/Hairy_cell_leukemia.jpg/345px-Hairy_cell_leukemia.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/9/91/Hairy_cell_leukemia.jpg 2x" data-file-width="433" data-file-height="295" /></a></td>
</tr>
<tr>
<th colspan="2" style="text-align:center">Classification and external resources</th>
</tr>
<tr>
<th scope="row"><a href="/wiki/Specialty_(medicine)" title="Specialty (medicine)">Specialty</a></th>
<td><a href="/wiki/Hematology" title="Hematology">Hematology</a> and <a href="/wiki/Oncology" title="Oncology">oncology</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/International_Statistical_Classification_of_Diseases_and_Related_Health_Problems" title="International Statistical Classification of Diseases and Related Health Problems">ICD</a>-<a href="/wiki/ICD-10" title="ICD-10">10</a></th>
<td><a rel="nofollow" class="external text" href="http://apps.who.int/classifications/icd10/browse/2015/en#/C91.4">C91.4</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/International_Statistical_Classification_of_Diseases_and_Related_Health_Problems" title="International Statistical Classification of Diseases and Related Health Problems">ICD</a>-<a href="/wiki/List_of_ICD-9_codes" title="List of ICD-9 codes">9-CM</a></th>
<td><a rel="nofollow" class="external text" href="http://www.icd9data.com/getICD9Code.ashx?icd9=202.4">202.4</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/International_Classification_of_Diseases_for_Oncology" title="International Classification of Diseases for Oncology">ICD-O</a></th>
<td><a href="/wiki/ICD-O" title="ICD-O" class="mw-redirect">M</a><a rel="nofollow" class="external text" href="http://www.progenetix.net/progenetix/I99403/">9940/3</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/Diseases_Database" title="Diseases Database">DiseasesDB</a></th>
<td><a rel="nofollow" class="external text" href="http://www.diseasesdatabase.com/ddb5589.htm">5589</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/MedlinePlus" title="MedlinePlus">MedlinePlus</a></th>
<td><a rel="nofollow" class="external text" href="http://www.nlm.nih.gov/medlineplus/ency/article/000592.htm">000592</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/EMedicine" title="EMedicine">eMedicine</a></th>
<td><a rel="nofollow" class="external text" href="http://www.emedicine.com/med/topic937.htm">med/937</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/Medical_Subject_Headings" title="Medical Subject Headings">MeSH</a></th>
<td><a rel="nofollow" class="external text" href="//www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&amp;term=D007943">D007943</a></td>
</tr>
</table>
<p><b>Hairy cell leukemia</b> is an uncommon <a href="/wiki/Hematological_malignancy" title="Hematological malignancy" class="mw-redirect">hematological malignancy</a> characterized by an accumulation of abnormal <a href="/wiki/B_lymphocyte" title="B lymphocyte" class="mw-redirect">B lymphocytes</a>. It is usually classified as a sub-type of <a href="/wiki/Chronic_lymphoid_leukemia" title="Chronic lymphoid leukemia" class="mw-redirect">chronic lymphoid leukemia</a>. Hairy cell leukemia makes up approximately 2% of all <a href="/wiki/Leukemia" title="Leukemia">leukemias</a>, with fewer than 2,000 new cases diagnosed annually in North America and Western Europe combined.</p>
<p>Hairy cell leukemia was originally described as histiocytic leukemia, malignant reticulosis, or lymphoid myelofibrosis in publications dating back to the 1920s. The disease was formally named leukemic reticuloendotheliosis and its characterization significantly advanced by <a href="/w/index.php?title=Bertha_Bouroncle&amp;action=edit&amp;redlink=1" class="new" title="Bertha Bouroncle (page does not exist)">Bertha Bouroncle</a> and colleagues at <a href="/wiki/OSU_College_of_Medicine_and_Public_Health" title="OSU College of Medicine and Public Health" class="mw-redirect">The Ohio State University College of Medicine</a> in 1958. Its common name, which was coined in 1966,<sup id="cite_ref-1" class="reference"><a href="#cite_note-1"><span>[</span>1<span>]</span></a></sup> is derived from the "hairy" appearance of the malignant B cells under a microscope.</p>
<p></p>
<div id="toc" class="toc">
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Classification"><span class="tocnumber">1</span> <span class="toctext">Classification</span></a>
<ul>
<li class="toclevel-2 tocsection-2"><a href="#Hairy_cell_leukemia-variant"><span class="tocnumber">1.1</span> <span class="toctext">Hairy cell leukemia-variant</span></a></li>
<li class="toclevel-2 tocsection-3"><a href="#Hairy_cell_leukemia-Japanese_variant"><span class="tocnumber">1.2</span> <span class="toctext">Hairy cell leukemia-Japanese variant</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-4"><a href="#Signs_and_symptoms"><span class="tocnumber">2</span> <span class="toctext">Signs and symptoms</span></a></li>
<li class="toclevel-1 tocsection-5"><a href="#Cause"><span class="tocnumber">3</span> <span class="toctext">Cause</span></a></li>
<li class="toclevel-1 tocsection-6"><a href="#Diagnosis"><span class="tocnumber">4</span> <span class="toctext">Diagnosis</span></a></li>
<li class="toclevel-1 tocsection-7"><a href="#Pathophysiology"><span class="tocnumber">5</span> <span class="toctext">Pathophysiology</span></a></li>
<li class="toclevel-1 tocsection-8"><a href="#Treatment"><span class="tocnumber">6</span> <span class="toctext">Treatment</span></a>
<ul>
<li class="toclevel-2 tocsection-9"><a href="#First-line_therapy:_purine_analog_chemotherapy"><span class="tocnumber">6.1</span> <span class="toctext">First-line therapy: purine analog chemotherapy</span></a></li>
<li class="toclevel-2 tocsection-10"><a href="#Second-line_therapy:_immunotherapy"><span class="tocnumber">6.2</span> <span class="toctext">Second-line therapy: immunotherapy</span></a></li>
<li class="toclevel-2 tocsection-11"><a href="#Other_treatment_options"><span class="tocnumber">6.3</span> <span class="toctext">Other treatment options</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-12"><a href="#Prognosis"><span class="tocnumber">7</span> <span class="toctext">Prognosis</span></a>
<ul>
<li class="toclevel-2 tocsection-13"><a href="#Treatment_success"><span class="tocnumber">7.1</span> <span class="toctext">Treatment success</span></a></li>
<li class="toclevel-2 tocsection-14"><a href="#Lifespan"><span class="tocnumber">7.2</span> <span class="toctext">Lifespan</span></a></li>
<li class="toclevel-2 tocsection-15"><a href="#Follow-up_care"><span class="tocnumber">7.3</span> <span class="toctext">Follow-up care</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-16"><a href="#Prevention.2FScreening"><span class="tocnumber">8</span> <span class="toctext">Prevention/Screening</span></a></li>
<li class="toclevel-1 tocsection-17"><a href="#Epidemiology"><span class="tocnumber">9</span> <span class="toctext">Epidemiology</span></a></li>
<li class="toclevel-1 tocsection-18"><a href="#Research_directions"><span class="tocnumber">10</span> <span class="toctext">Research directions</span></a></li>
<li class="toclevel-1 tocsection-19"><a href="#See_also"><span class="tocnumber">11</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1 tocsection-20"><a href="#References"><span class="tocnumber">12</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1 tocsection-21"><a href="#External_links"><span class="tocnumber">13</span> <span class="toctext">External links</span></a></li>
</ul>
</div>
<p></p>
<h2><span class="mw-headline" id="Classification">Classification</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Hairy_cell_leukemia&amp;action=edit&amp;section=1" title="Edit section: Classification">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>When not further specified, the "classic" form is often implied. However, two variants have been described: Hairy cell leukemia-variant,<sup id="cite_ref-urlAmerican_Journal_of_Clinical_Pathology_2-0" class="reference"><a href="#cite_note-urlAmerican_Journal_of_Clinical_Pathology-2"><span>[</span>2<span>]</span></a></sup> which usually is diagnosed in men, and a Japanese variant. The non-Japanese variant is more difficult to treat than either 'classic' HCL or the Japanese variant HCL.</p>
<h3><span class="mw-headline" id="Hairy_cell_leukemia-variant">Hairy cell leukemia-variant</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Hairy_cell_leukemia&amp;action=edit&amp;section=2" title="Edit section: Hairy cell leukemia-variant">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p><b>Hairy cell leukemia-variant</b>, or HCL-V, is usually described as a prolymphocytic variant of hairy cell leukemia.<sup id="cite_ref-bloodjournal.hematologylibrary.org_3-0" class="reference"><a href="#cite_note-bloodjournal.hematologylibrary.org-3"><span>[</span>3<span>]</span></a></sup> It was first formally described in 1980 by a paper from the University of Cambridge's Hayhoe lab.<sup id="cite_ref-pmid7206776_4-0" class="reference"><a href="#cite_note-pmid7206776-4"><span>[</span>4<span>]</span></a></sup> About 10% of HCL patients have this variant form of the disease, representing about 60-75 new HCL-V patients each year in the U.S. While classic HCL primarily affects men, HCL-V is more evenly divided between males and females.<sup id="cite_ref-pmid11243388_5-0" class="reference"><a href="#cite_note-pmid11243388-5"><span>[</span>5<span>]</span></a></sup> While the disease can appear at any age, the median age at diagnosis is over 70.<sup id="cite_ref-pmid15737038_6-0" class="reference"><a href="#cite_note-pmid15737038-6"><span>[</span>6<span>]</span></a></sup></p>
<p>Similar to <a href="/wiki/B-cell_prolymphocytic_leukemia" title="B-cell prolymphocytic leukemia">B-cell prolymphocytic leukemia</a> ("B-PLL") in <a href="/wiki/Chronic_lymphocytic_leukemia" title="Chronic lymphocytic leukemia" class="mw-redirect">Chronic lymphocytic leukemia</a>, HCL-V is a more aggressive disease. It is less likely to be treated successfully than is classic HCL, and remissions tend to be shorter. Many treatment approaches, such as <a href="/wiki/Interferon" title="Interferon">Interferon</a>-<i>alpha</i>, the combination chemotherapy regimen "CHOP", and common alkylating agents like <a href="/wiki/Cyclophosphamide" title="Cyclophosphamide">cyclophosphamide</a> provide very little benefit.<sup id="cite_ref-pmid11243388_5-1" class="reference"><a href="#cite_note-pmid11243388-5"><span>[</span>5<span>]</span></a></sup> Pentostatin and cladribine provide some benefit to many HCL-V patients, but typically induce shorter remission periods and lower response rates than when they are used in classic HCL. More than half of victims respond partially to splenectomy.<sup id="cite_ref-pmid11243388_5-2" class="reference"><a href="#cite_note-pmid11243388-5"><span>[</span>5<span>]</span></a></sup></p>
<p>In terms of B-cell development, the <a href="/wiki/Prolymphocytes" title="Prolymphocytes" class="mw-redirect">prolymphocytes</a> are less developed than are <a href="/wiki/Lymphocytes" title="Lymphocytes" class="mw-redirect">lymphocytes</a> or <a href="/wiki/Plasma_cells" title="Plasma cells" class="mw-redirect">plasma cells</a>, but are still more mature than their <a href="/wiki/Lymphoblast" title="Lymphoblast">lymphoblastic</a> precursors.</p>
<p>HCL-V differs from classic HCL principally in the following respects:</p>
<ul>
<li>Higher <a href="/wiki/White_blood_cell" title="White blood cell">white blood cell</a> counts, sometimes exceeding 100,000 cells per microliter;</li>
<li>A more aggressive course of disease requiring more frequent treatment;</li>
<li>Hairy cells with an unusually large <a href="/wiki/Nucleolus" title="Nucleolus">nucleolus</a> for their size;</li>
<li>Production of little excess <a href="/wiki/Fibronectin" title="Fibronectin">fibronectin</a> produced by classic hairy cells;<sup id="cite_ref-7" class="reference"><a href="#cite_note-7"><span>[</span>7<span>]</span></a></sup> to interfere with bone marrow biopsies; and</li>
<li>Low or no cell-surface expression of <a href="/wiki/CD25" title="CD25">CD25</a> (also called the Interleukin-2 [IL-2] receptor <i>alpha</i> chain, or p55).<sup id="cite_ref-8" class="reference"><a href="#cite_note-8"><span>[</span>8<span>]</span></a></sup></li>
</ul>
<p>Low levels of CD25, a part of the receptor for a key immunoregulating hormone, may explain why HCL-V cases are generally much more resistant to treatment by immune system hormones.<sup id="cite_ref-bloodjournal.hematologylibrary.org_3-1" class="reference"><a href="#cite_note-bloodjournal.hematologylibrary.org-3"><span>[</span>3<span>]</span></a></sup></p>
<p>HCL-V, which usually features a high proportion of hairy cells without a functional <a href="/wiki/P53" title="P53">p53</a> <a href="/wiki/Tumor_suppressor_gene" title="Tumor suppressor gene">tumor suppressor gene</a>, is somewhat more likely to transform into a higher-grade malignancy. A typical transformation rate of 5%-6% has been postulated in the U.K., similar to the <a href="/wiki/Richter%27s_transformation" title="Richter's transformation">Richter's transformation</a> rate for SLVL and CLL.<sup id="cite_ref-pmid11243388_5-3" class="reference"><a href="#cite_note-pmid11243388-5"><span>[</span>5<span>]</span></a></sup><sup id="cite_ref-pmid12670464_9-0" class="reference"><a href="#cite_note-pmid12670464-9"><span>[</span>9<span>]</span></a></sup> Among HCL-V patients, the most aggressive cases normally have the least amount of p53 gene activity.<sup id="cite_ref-pmid10576509_10-0" class="reference"><a href="#cite_note-pmid10576509-10"><span>[</span>10<span>]</span></a></sup> Hairy cells without the p53 gene tend, over time, to displace the less aggressive p53(+) hairy cells.</p>
<h3><span class="mw-headline" id="Hairy_cell_leukemia-Japanese_variant">Hairy cell leukemia-Japanese variant</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Hairy_cell_leukemia&amp;action=edit&amp;section=3" title="Edit section: Hairy cell leukemia-Japanese variant">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p><b>Hairy cell leukemia-Japanese variant</b> or HCL-J. There is also a Japanese variant, which is more easily treated.</p>
<p>Treatment with <a href="/wiki/Cladribine" title="Cladribine">cladribine</a> has been reported.<sup id="cite_ref-pmid15199752_11-0" class="reference"><a href="#cite_note-pmid15199752-11"><span>[</span>11<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Signs_and_symptoms">Signs and symptoms</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Hairy_cell_leukemia&amp;action=edit&amp;section=4" title="Edit section: Signs and symptoms">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>In hairy cell leukemia, the "hairy cells" (malignant B lymphocytes) accumulate in the bone marrow, interfering with the production of normal <a href="/wiki/White_blood_cells" title="White blood cells" class="mw-redirect">white blood cells</a>, <a href="/wiki/Red_blood_cells" title="Red blood cells" class="mw-redirect">red blood cells</a>, and <a href="/wiki/Platelets" title="Platelets" class="mw-redirect">platelets</a>. Consequently, patients may develop infections related to <a href="/wiki/Neutropenia" title="Neutropenia">low white blood cell count</a>, <a href="/wiki/Anemia" title="Anemia">anemia</a> and fatigue due to a lack of red blood cells, or easy bleeding due to a <a href="/wiki/Thrombocytopenia" title="Thrombocytopenia">low platelet count</a>.<sup id="cite_ref-12" class="reference"><a href="#cite_note-12"><span>[</span>12<span>]</span></a></sup> Leukemic cells may gather in the <a href="/wiki/Spleen" title="Spleen">spleen</a> and cause it to swell; this can have the side effect of making the person feel full even when he or she has not eaten much.</p>
<p>Hairy cell leukemia is commonly diagnosed after a routine blood count shows unexpectedly low numbers of one or more kinds of normal blood cells, or after unexplained bruises or recurrent infections in an otherwise apparently healthy patient.</p>
<p>Platelet function may be somewhat impaired in HCL patients, although this does not appear to have any significant practical effect.<sup id="cite_ref-pmid512041_13-0" class="reference"><a href="#cite_note-pmid512041-13"><span>[</span>13<span>]</span></a></sup> It may result in somewhat more mild bruises than would otherwise be expected for a given platelet count or a mildly increased bleeding time for a minor cut. It is likely the result of producing slightly abnormal platelets in the overstressed bone marrow tissue.</p>
<p>Patients with a high tumor burden may also have somewhat reduced levels of cholesterol,<sup id="cite_ref-14" class="reference"><a href="#cite_note-14"><span>[</span>14<span>]</span></a></sup> especially in patients with an enlarged spleen.<sup id="cite_ref-15" class="reference"><a href="#cite_note-15"><span>[</span>15<span>]</span></a></sup> Cholesterol levels return to more normal values with successful treatment of HCL.</p>
<h2><span class="mw-headline" id="Cause">Cause</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Hairy_cell_leukemia&amp;action=edit&amp;section=5" title="Edit section: Cause">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>As with many cancers, the cause of hairy cell leukemia is unknown. Exposure to tobacco smoke, <a href="/wiki/Ionizing_radiation" title="Ionizing radiation">ionizing radiation</a>, or industrial chemicals (with the possible exception of <a href="/wiki/Diesel_fuel" title="Diesel fuel">diesel</a>) does not appear to increase the risk of developing HCL.<sup id="cite_ref-pmid7577624_16-0" class="reference"><a href="#cite_note-pmid7577624-16"><span>[</span>16<span>]</span></a></sup> Farming and gardening appear to increase the risk of HCL in some studies.<sup id="cite_ref-pmid11083509_17-0" class="reference"><a href="#cite_note-pmid11083509-17"><span>[</span>17<span>]</span></a></sup></p>
<p>Recent studies have identified somatic BRAF V600E mutations in all patients with the classic form of hairy cell leukemia thus sequenced, but in no patients with the variant form.<sup id="cite_ref-pmid21663470_18-0" class="reference"><a href="#cite_note-pmid21663470-18"><span>[</span>18<span>]</span></a></sup></p>
<p>The U.S. <a href="/wiki/Institute_of_Medicine" title="Institute of Medicine">Institute of Medicine</a> (IOM) announced "sufficient evidence" of an association between exposure to herbicides and later development of chronic B-cell leukemias and lymphomas in general. The IOM report emphasized that neither animal nor human studies indicate an association of herbicides with HCL specifically. However, the IOM extrapolated data from chronic lymphocytic leukemia and <a href="/wiki/Non-Hodgkin_lymphoma" title="Non-Hodgkin lymphoma">non-Hodgkin lymphoma</a> to conclude that HCL and other rare B-cell neoplasms may share this risk factor.<sup id="cite_ref-19" class="reference"><a href="#cite_note-19"><span>[</span>19<span>]</span></a></sup> As a result of the IOM report, the U.S. <a href="/wiki/United_States_Department_of_Veterans_Affairs" title="United States Department of Veterans Affairs">Department of Veterans Affairs</a> considers HCL an illnesses presumed to be a service-related disability (see <a href="/wiki/Agent_Orange" title="Agent Orange">Agent Orange</a>).</p>
<p><a href="/wiki/Human_T-lymphotropic_virus_2" title="Human T-lymphotropic virus 2">Human T-lymphotropic virus 2</a> (HTLV-2) has been isolated in a small number of patients with the variant form of HCL.<sup id="cite_ref-pmid16155606_20-0" class="reference"><a href="#cite_note-pmid16155606-20"><span>[</span>20<span>]</span></a></sup> In the 1980s, HTLV-2 was identified in a patient with a T-cell lymphoproliferative disease; this patient later developed hairy cell leukemia (a B cell disease), but HTLV-2 was not found in the hairy cell clones.<sup id="cite_ref-pmid2827811_21-0" class="reference"><a href="#cite_note-pmid2827811-21"><span>[</span>21<span>]</span></a></sup> There is no evidence that HTLV-II causes any sort of hematological malignancy, including HCL.<sup id="cite_ref-pmid15595431_22-0" class="reference"><a href="#cite_note-pmid15595431-22"><span>[</span>22<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Diagnosis">Diagnosis</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Hairy_cell_leukemia&amp;action=edit&amp;section=6" title="Edit section: Diagnosis">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>The diagnosis of HCL may be suggested by abnormal results on a <a href="/wiki/Complete_blood_count" title="Complete blood count">complete blood count</a> (CBC), but additional testing is necessary to confirm the diagnosis. A CBC normally shows low counts for white blood cells, red blood cells, and platelets in HCL patients. However, if large numbers of hairy cells are in the blood stream, then normal or even <a href="/wiki/Lymphocytosis" title="Lymphocytosis">high lymphocyte counts</a> may be found.</p>
<p>On physical exam, 80–90% of patients have an <a href="/wiki/Splenomegaly" title="Splenomegaly">enlarged spleen</a>, which can be massive.<sup id="cite_ref-Wintrobe_23-0" class="reference"><a href="#cite_note-Wintrobe-23"><span>[</span>23<span>]</span></a></sup> This is less likely among patients who are diagnosed at an early stage. Peripheral <a href="/wiki/Lymphadenopathy" title="Lymphadenopathy">lymphadenopathy</a> (enlarged lymph nodes) is uncommon (less than 5% of patients), but abdominal lymphadenopathy is a relatively common finding on <a href="/wiki/Computed_tomography" title="Computed tomography" class="mw-redirect">computed tomography</a> (CT) scans.<sup id="cite_ref-Wintrobe_23-1" class="reference"><a href="#cite_note-Wintrobe-23"><span>[</span>23<span>]</span></a></sup></p>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Hairy_cell_leukemia_smear_2009-08-20.JPG" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/e4/Hairy_cell_leukemia_smear_2009-08-20.JPG/220px-Hairy_cell_leukemia_smear_2009-08-20.JPG" width="220" height="165" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/e4/Hairy_cell_leukemia_smear_2009-08-20.JPG/330px-Hairy_cell_leukemia_smear_2009-08-20.JPG 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/e4/Hairy_cell_leukemia_smear_2009-08-20.JPG/440px-Hairy_cell_leukemia_smear_2009-08-20.JPG 2x" data-file-width="895" data-file-height="670" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Hairy_cell_leukemia_smear_2009-08-20.JPG" class="internal" title="Enlarge"></a></div>
Hairy cell leukemia: abnormal B cells look "hairy" under a microscope because of radial projections from their surface.</div>
</div>
</div>
<p>The most important lab finding is the presence of hairy cells in the bloodstream.<sup id="cite_ref-Wintrobe_23-2" class="reference"><a href="#cite_note-Wintrobe-23"><span>[</span>23<span>]</span></a></sup> Hairy cells are abnormal <a href="/wiki/White_blood_cell" title="White blood cell">white blood cells</a> with hair-like projections of <a href="/wiki/Cytoplasm" title="Cytoplasm">cytoplasm</a>; they can be seen by examining a <a href="/wiki/Blood_smear" title="Blood smear" class="mw-redirect">blood smear</a> or <a href="/wiki/Bone_marrow_biopsy" title="Bone marrow biopsy" class="mw-redirect">bone marrow biopsy</a> specimen. The blood film examination is done by <a href="/wiki/Staining" title="Staining">staining</a> the blood cells with <a href="/wiki/Wright%27s_stain" title="Wright's stain">Wright's stain</a> and looking at them under a <a href="/wiki/Microscope" title="Microscope">microscope</a>. Hairy cells are visible in this test in about 85% of cases.<sup id="cite_ref-Wintrobe_23-3" class="reference"><a href="#cite_note-Wintrobe-23"><span>[</span>23<span>]</span></a></sup></p>
<p>Most patients require a bone marrow biopsy for final diagnosis. The bone marrow biopsy is used both to confirm the presence of HCL and also the absence of any additional diseases, such as <a href="/wiki/Splenic_marginal_zone_lymphoma" title="Splenic marginal zone lymphoma">Splenic marginal zone lymphoma</a> or <a href="/wiki/B-cell_prolymphocytic_leukemia" title="B-cell prolymphocytic leukemia">B-cell prolymphocytic leukemia</a>. The diagnosis can be confirmed by viewing the cells with a special stain known as TRAP (<a href="/wiki/Tartrate_resistant_acid_phosphatase" title="Tartrate resistant acid phosphatase" class="mw-redirect">tartrate resistant acid phosphatase</a>).</p>
<p>It is also possible to definitively diagnose hairy cell leukemia through <a href="/wiki/Flow_cytometry" title="Flow cytometry">flow cytometry</a> on blood or bone marrow. The hairy cells are larger than normal and positive for <a href="/wiki/CD19" title="CD19">CD19</a>, <a href="/wiki/CD20" title="CD20">CD20</a>, <a href="/wiki/CD22" title="CD22">CD22</a>, <a href="/wiki/CD11c" title="CD11c">CD11c</a>, <a href="/wiki/CD25" title="CD25">CD25</a>, <a href="/wiki/CD103" title="CD103" class="mw-redirect">CD103</a>, and <a href="/wiki/FMC7" title="FMC7" class="mw-redirect">FMC7</a>.<sup id="cite_ref-24" class="reference"><a href="#cite_note-24"><span>[</span>24<span>]</span></a></sup> (<a href="/wiki/CD103" title="CD103" class="mw-redirect">CD103</a>, <a href="/wiki/CD22" title="CD22">CD22</a>, and <a href="/wiki/CD11c" title="CD11c">CD11c</a> are strongly expressed.)<sup id="cite_ref-pmid18798068_25-0" class="reference"><a href="#cite_note-pmid18798068-25"><span>[</span>25<span>]</span></a></sup></p>
<p>Hairy cell leukemia-variant (HCL-V), which shares some characteristics with B cell prolymphocytic leukemia (B-PLL), does not show CD25 (also called the Interleukin-2 receptor, alpha). As this is relatively new and expensive technology, its adoption by physicians is not uniform, despite the advantages of comfort, simplicity, and safety for the patient when compared to a bone marrow biopsy. The presence of additional <a href="/wiki/Lymphoproliferative_disease" title="Lymphoproliferative disease" class="mw-redirect">lymphoproliferative diseases</a> is easily checked during a flow cytometry test, where they characteristically show different results.<sup id="cite_ref-pmid16880237_26-0" class="reference"><a href="#cite_note-pmid16880237-26"><span>[</span>26<span>]</span></a></sup></p>
<p>The differential diagnoses include: several kinds of <a href="/wiki/Anemia" title="Anemia">anemia</a>, including <a href="/wiki/Myelophthisis" title="Myelophthisis" class="mw-redirect">myelophthisis</a> and <a href="/wiki/Aplastic_anemia" title="Aplastic anemia">aplastic anemia</a>,<sup id="cite_ref-27" class="reference"><a href="#cite_note-27"><span>[</span>27<span>]</span></a></sup> and most kinds of blood neoplasms, including hypoplastic <a href="/wiki/Myelodysplastic_syndrome" title="Myelodysplastic syndrome">myelodysplastic syndrome</a>, atypical chronic lymphocytic leukemia, <a href="/wiki/B-cell_prolymphocytic_leukemia" title="B-cell prolymphocytic leukemia">B-cell prolymphocytic leukemia</a>, or idiopathic <a href="/wiki/Myelofibrosis" title="Myelofibrosis">myelofibrosis</a>.<sup id="cite_ref-pmid16880237_26-1" class="reference"><a href="#cite_note-pmid16880237-26"><span>[</span>26<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Pathophysiology">Pathophysiology</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Hairy_cell_leukemia&amp;action=edit&amp;section=7" title="Edit section: Pathophysiology">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p><a href="/wiki/Pancytopenia" title="Pancytopenia">Pancytopenia</a> in HCL is caused primarily by marrow failure and <a href="/wiki/Splenomegaly" title="Splenomegaly">splenomegaly</a>. Bone marrow failure is caused by the accumulation of hairy cells and reticulin <a href="/wiki/Fibrosis" title="Fibrosis">fibrosis</a> in the bone marrow, as well as by the detrimental effects of dysregulated cytokine production.<sup id="cite_ref-Wintrobe_23-4" class="reference"><a href="#cite_note-Wintrobe-23"><span>[</span>23<span>]</span></a></sup> Splenomegaly reduces blood counts through sequestration, marginalization, and destruction of healthy blood cells inside the spleen.<sup id="cite_ref-Wintrobe_23-5" class="reference"><a href="#cite_note-Wintrobe-23"><span>[</span>23<span>]</span></a></sup></p>
<p>Hairy cells are nearly mature <a href="/wiki/B_cell" title="B cell">B cells</a>, which are activated clonal cells with signs of VH gene differentiation.<sup id="cite_ref-pmid16880237_26-2" class="reference"><a href="#cite_note-pmid16880237-26"><span>[</span>26<span>]</span></a></sup> They may be related to pre-plasma <a href="/wiki/Marginal_zone" title="Marginal zone">marginal zone</a> B cells<sup id="cite_ref-Wintrobe_23-6" class="reference"><a href="#cite_note-Wintrobe-23"><span>[</span>23<span>]</span></a></sup> or <a href="/wiki/Memory_cells" title="Memory cells" class="mw-redirect">memory cells</a>.</p>
<p><a href="/wiki/Cytokine" title="Cytokine">Cytokine</a> production is disturbed in HCL. Hairy cells produce and thrive on <a href="/wiki/TNF-alpha" title="TNF-alpha" class="mw-redirect">TNF-alpha</a>.<sup id="cite_ref-Wintrobe_23-7" class="reference"><a href="#cite_note-Wintrobe-23"><span>[</span>23<span>]</span></a></sup> This cytokine also suppresses normal production of healthy blood cells in the bone marrow.<sup id="cite_ref-Wintrobe_23-8" class="reference"><a href="#cite_note-Wintrobe-23"><span>[</span>23<span>]</span></a></sup></p>
<p>Unlike healthy B cells, hairy cells express and secrete an immune system protein called <a href="/wiki/Interleukin-2_receptor" title="Interleukin-2 receptor" class="mw-redirect">Interleukin-2 receptor</a> (IL-2R).<sup id="cite_ref-Wintrobe_23-9" class="reference"><a href="#cite_note-Wintrobe-23"><span>[</span>23<span>]</span></a></sup> In HCL-V, only part of this receptor is expressed.<sup id="cite_ref-Wintrobe_23-10" class="reference"><a href="#cite_note-Wintrobe-23"><span>[</span>23<span>]</span></a></sup> As a result, disease status can be monitored by measuring changes in the amount of IL-2R in the blood serum.<sup id="cite_ref-Wintrobe_23-11" class="reference"><a href="#cite_note-Wintrobe-23"><span>[</span>23<span>]</span></a></sup> The level increases as hairy cells proliferate, and decreases when they are killed. Although uncommonly used in North America and northern Europe, this test correlates better with disease status and predicts relapse more accurately than any other test.</p>
<p>Hairy cells respond to normal production of some cytokines by <a href="/wiki/T_cell" title="T cell">T cells</a> with increased growth. Treatment with Interferon-alpha suppresses the production of this pro-growth cytokine from T cells.<sup id="cite_ref-Wintrobe_23-12" class="reference"><a href="#cite_note-Wintrobe-23"><span>[</span>23<span>]</span></a></sup> A low level of T cells, which is commonly seen after treatment with <a href="/wiki/Cladribine" title="Cladribine">cladribine</a> or <a href="/wiki/Pentostatin" title="Pentostatin">pentostatin</a>, and the consequent reduction of these cytokines, is also associated with reduced levels of hairy cells.</p>
<p>In June 2011, E Tiacci <i>et al</i><sup id="cite_ref-TiacciTrifonov2011_28-0" class="reference"><a href="#cite_note-TiacciTrifonov2011-28"><span>[</span>28<span>]</span></a></sup> <sup id="cite_ref-29" class="reference"><a href="#cite_note-29"><span>[</span>29<span>]</span></a></sup> discovered that 100% of hairy-cell leukaemia samples analysed had the oncogenic <a href="/wiki/BRAF_(gene)" title="BRAF (gene)">BRAF</a> mutation V600E, and proposed that this is the disease's driver mutation. Until this point, only a few <a href="/wiki/Comparative_genomic_hybridization" title="Comparative genomic hybridization">genomic</a> imbalances had been found in the hairy cells, such as <a href="/wiki/Trisomy" title="Trisomy">trisomy</a> 5 had been found.<sup id="cite_ref-Wintrobe_23-13" class="reference"><a href="#cite_note-Wintrobe-23"><span>[</span>23<span>]</span></a></sup> The <a href="/wiki/Gene_expression" title="Gene expression">expression of genes</a> is also dysregulated in a complex and specific pattern. The cells underexpress 3p24, 3p21, 3q13.3-q22, 4p16, 11q23, 14q22-q24, 15q21-q22, 15q24-q25, and 17q22-q24 and overexpress 13q31 and Xq13.3-q21.<sup id="cite_ref-30" class="reference"><a href="#cite_note-30"><span>[</span>30<span>]</span></a></sup> It has not yet been demonstrated that any of these changes have any practical significance to the patient.</p>
<h2><span class="mw-headline" id="Treatment">Treatment</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Hairy_cell_leukemia&amp;action=edit&amp;section=8" title="Edit section: Treatment">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Several treatments are available, and successful control of the disease is common.</p>
<p><b>Not everyone needs treatment.</b> Treatment is usually given when the symptoms of the disease interfere with the patient's everyday life, or when white blood cell or platelet counts decline to dangerously low levels, such as an <a href="/wiki/Absolute_neutrophil_count" title="Absolute neutrophil count">absolute neutrophil count</a> below one thousand cells per microliter (1.0 K/uL). Not all patients need treatment immediately upon diagnosis, and about 10% of patients will never need treatment.</p>
<p><b>Treatment delays are less important than in solid tumors.</b> Unlike most cancers, treatment success does not depend on treating the disease at an early stage. Because delays do not affect treatment success, there are no standards for how quickly a patient should receive treatment. However, waiting too long can cause its own problems, such as an infection that might have been avoided by proper treatment to restore immune system function. Also, having a higher number of hairy cells at the time of treatment can make certain side effects somewhat worse, as some side effects are primarily caused by the body's natural response to the dying hairy cells. This can result in the hospitalization of a patient whose treatment would otherwise be carried out entirely at the hematologist's office.</p>
<p><b>Single-drug treatment is typical.</b> Unlike most cancers, only one drug is normally given to a patient at a time. While monotherapy is normal, combination therapy—typically using one first-line therapy and one second-line therapy—is being studied in current clinical trials and is used more frequently for refractory cases. Combining rituximab with cladribine or pentostatin may or may not produce any practical benefit to the patient.<sup id="cite_ref-pmid16497968_31-0" class="reference"><a href="#cite_note-pmid16497968-31"><span>[</span>31<span>]</span></a></sup> Combination therapy is almost never used with a new patient. Because the success rates with purine analog monotherapy are already so high, the additional benefit from immediate treatment with a second drug in a treatment-naïve patient is assumed to be very low. For example, one round of either cladribine or pentostatin gives the median first-time patient a decade-long remission; the addition of rituximab, which gives the median patient only three or four years, might provide no additional value for this easily treated patient. In a more difficult case, however, the benefit from the first drug may be substantially reduced and therefore a combination may provide some benefit.</p>
<h3><span class="mw-headline" id="First-line_therapy:_purine_analog_chemotherapy">First-line therapy: purine analog chemotherapy</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Hairy_cell_leukemia&amp;action=edit&amp;section=9" title="Edit section: First-line therapy: purine analog chemotherapy">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p><a href="/wiki/Cladribine" title="Cladribine">Cladribine</a> (2CDA) and <a href="/wiki/Pentostatin" title="Pentostatin">pentostatin</a> (DCF) are the two most common first-line therapies. They both belong to a class of medications called <a href="/wiki/Purine_analog" title="Purine analog" class="mw-redirect">purine analogs</a>, which have mild side effects compared to traditional <a href="/wiki/Chemotherapy" title="Chemotherapy">chemotherapy</a> regimens.</p>
<p>Cladribine can be administered by injection under the skin, by infusion over a couple of hours into a vein, or by a pump worn by the patient that provides a slow drip into a vein, 24 hours a day for 7 days. Most patients receive cladribine by IV infusion once a day for five to seven days, but more patients are being given the option of taking this drug once a week for six weeks. The different dosing schedules used with cladribine are approximately equally effective and equally safe.<sup id="cite_ref-32" class="reference"><a href="#cite_note-32"><span>[</span>32<span>]</span></a></sup> Relatively few patients have significant side effects other than fatigue and a high fever caused by the cancer cells dying, although complications like infection and acute kidney failure have been seen.</p>
<p>Pentostatin is chemically similar to cladribine, and has a similar success rate and side effect profile, but it is always given over a much longer period of time, usually one dose by IV infusion every two weeks for three to six months.</p>
<p>During the weeks following treatment the patient's <a href="/wiki/Immune_system" title="Immune system">immune system</a> is severely weakened, but their <a href="/wiki/Bone_marrow" title="Bone marrow">bone marrow</a> will begin to produce normal blood cells again. Treatment often results in long-term remission. About 85% of patients achieve a complete response from treatment with either cladribine or pentostatin, and another 10% receive some benefit from these drugs, although there is no permanent cure for this disease. If the cancer cells return, the treatment may be repeated and should again result in remission, although the odds of success decline with repeated treatment.<sup id="cite_ref-pmid16245328_33-0" class="reference"><a href="#cite_note-pmid16245328-33"><span>[</span>33<span>]</span></a></sup> Remission lengths vary significantly, from one year to more than twenty years. The median patient can expect a treatment-free interval of about ten years.</p>
<p>It does not seem to matter which drug a patient receives. A patient who is not successfully treated with one of these two drugs has a reduced chance of being successfully treated with the other. However, there are other options.</p>
<h3><span class="mw-headline" id="Second-line_therapy:_immunotherapy">Second-line therapy: immunotherapy</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Hairy_cell_leukemia&amp;action=edit&amp;section=10" title="Edit section: Second-line therapy: immunotherapy">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>If a patient is resistant to either cladribine or pentostatin, then second-line therapy is pursued.</p>
<p><b>Monoclonal antibodies</b> The most common treatment for cladribine-resistant disease is infusing monoclonal antibodies that destroy cancerous B cells. <a href="/wiki/Rituximab" title="Rituximab">Rituximab</a> is by far the most commonly used. Most patients receive one IV infusion over several hours each week for four to eight weeks. A 2003 publication found two partial and ten complete responses out of 15 patients with relapsed disease, for a total of 80% responding.<sup id="cite_ref-34" class="reference"><a href="#cite_note-34"><span>[</span>34<span>]</span></a></sup> The median patient (including non-responders) did not require further treatment for more than three years. This eight-dose study had a higher response rate than a four-dose study at Scripps, which achieved only 25% response rate.<sup id="cite_ref-35" class="reference"><a href="#cite_note-35"><span>[</span>35<span>]</span></a></sup> Rituximab has successfully induced a complete response in Hairy Cell-Variant.<sup id="cite_ref-36" class="reference"><a href="#cite_note-36"><span>[</span>36<span>]</span></a></sup></p>
<p>Rituximab's major side effect is serum sickness, commonly described as an "allergic reaction", which can be severe, especially on the first infusion. Serum sickness is primarily caused by the antibodies clumping during infusion and triggering the <a href="/wiki/Complement_system" title="Complement system">complement</a> cascade. Although most patients find that side effects are adequately controlled by anti-allergy drugs, some severe, and even fatal, reactions have occurred. Consequently, the first dose is always given in a hospital setting, although subsequent infusions may be given in a physician's office. Remissions are usually shorter than with the preferred first-line drugs, but hematologic remissions of several years' duration are not uncommon.</p>
<p>Other B cell-destroying monoclonal antibodies such as <a href="/wiki/Alemtuzumab" title="Alemtuzumab">Alemtuzumab</a>, <a href="/wiki/Ibritumomab_tiuxetan" title="Ibritumomab tiuxetan">Ibritumomab tiuxetan</a> and I-131 <a href="/wiki/Tositumomab" title="Tositumomab">Tositumomab</a> may be considered for refractory cases.</p>
<p><b>Interferon-alpha</b> <a href="/wiki/Interferon-alpha" title="Interferon-alpha" class="mw-redirect">Interferon-alpha</a> is an immune system hormone that is very helpful to a relatively small number of patients, and somewhat helpful to most patients. In about 65% of patients,<sup id="cite_ref-37" class="reference"><a href="#cite_note-37"><span>[</span>37<span>]</span></a></sup> the drug helps stabilize the disease or produce a slow, minor improvement for a partial response.<sup id="cite_ref-38" class="reference"><a href="#cite_note-38"><span>[</span>38<span>]</span></a></sup></p>
<p>The typical dosing schedule injects at least 3 million units of Interferon-alpha (not pegylated versions) three times a week, although the original protocol began with six months of daily injections.</p>
<p>Some patients tolerate IFN-alpha very well after the first couple of weeks, while others find that its characteristic <a href="/wiki/Flu-like_symptoms" title="Flu-like symptoms" class="mw-redirect">flu-like symptoms</a> persist. About 10% of patients develop a level of <a href="/wiki/Depression_(mood)" title="Depression (mood)">depression</a>. It is possible that, by maintaining a steadier level of the hormone in the body, that daily injections might cause fewer side effects in selected patients. Drinking at least two liters of water each day, while avoiding caffeine and alcohol, can reduce many of the side effects.</p>
<p>A drop in blood counts is usually seen during the first one to two months of treatment. Most patients find that their blood counts get worse for a few weeks immediately after starting treatment, although some patients find their blood counts begin to improve within just two weeks.<sup id="cite_ref-pmid3971043_39-0" class="reference"><a href="#cite_note-pmid3971043-39"><span>[</span>39<span>]</span></a></sup></p>
<p>It typically takes six months to figure out whether this therapy is useful. Common criteria for treatment success include:</p>
<ul>
<li>normalization of hemoglobin levels (above 12.0 g/dL),</li>
<li>a normal or somewhat low platelet count (above 100 K/µL), and</li>
<li>a normal or somewhat low absolute neutrophil count (above 1.5 K/µL).<sup id="cite_ref-pmid3971043_39-1" class="reference"><a href="#cite_note-pmid3971043-39"><span>[</span>39<span>]</span></a></sup></li>
</ul>
<p>If it is well tolerated, patients usually take the hormone for 12 to 18 months. An attempt may be made then to end the treatment, but most patients discover that they need to continue taking the drug for it to be successful. These patients often continue taking this drug indefinitely, until either the disease becomes resistant to this hormone, or the body produces an immune system response that limits the drug's ability to function. A few patients are able to achieve a sustained clinical remission after taking this drug for six months to one year. This may be more likely when IFN-alpha has been initiated shortly after another therapy. Interferon-alpha is considered the drug of choice for pregnant women with active HCL, although it carries some risks, such as the potential for decreased blood flow to the placenta.</p>
<p>Interferon-alpha works by sensitizing the hairy cells to the killing effect of the immune system hormone TNF-alpha, whose production it promotes.<sup id="cite_ref-pmid12091360_40-0" class="reference"><a href="#cite_note-pmid12091360-40"><span>[</span>40<span>]</span></a></sup> IFN-alpha works best on classic hairy cells that are not protectively adhered to vitronectin or fibronectin, which suggests that patients who encounter less fibrous tissue in their bone marrow biopsies may be more likely to respond to Interferon-alpha therapy. It also explains why non-adhered hairy cells, such as those in the bloodstream, disappear during IFN-alpha treatment well before reductions are seen in adhered hairy cells, such as those in the bone marrow and spleen.<sup id="cite_ref-pmid12091360_40-1" class="reference"><a href="#cite_note-pmid12091360-40"><span>[</span>40<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Other_treatment_options">Other treatment options</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Hairy_cell_leukemia&amp;action=edit&amp;section=11" title="Edit section: Other treatment options">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p><b><a href="/wiki/Splenectomy" title="Splenectomy">Splenectomy</a></b> can produce long-term remissions in patients whose spleens seem to be heavily involved, but its success rate is noticeably lower than cladribine or pentostatin. Splenectomies are also performed for patients whose persistently enlarged spleens cause significant discomfort or in patients whose persistently low platelet counts suggest <a href="/wiki/Idiopathic_thrombocytopenic_purpura" title="Idiopathic thrombocytopenic purpura">Idiopathic thrombocytopenic purpura</a>.</p>
<p><b><a href="/wiki/Bone_marrow_transplant" title="Bone marrow transplant" class="mw-redirect">Bone marrow transplants</a></b> are usually shunned in this highly treatable disease because of the inherent risks in the procedure. They may be considered for refractory cases in younger, otherwise healthy individuals. "Mini-transplants" are possible.</p>
<p>Patients with <a href="/wiki/Anemia" title="Anemia">anemia</a> or <a href="/wiki/Thrombocytopenia" title="Thrombocytopenia">thrombocytopenia</a> may also receive red blood cells and platelets through <b><a href="/wiki/Blood_transfusions" title="Blood transfusions" class="mw-redirect">blood transfusions</a></b>. Blood transfusions are always irradiated to remove white blood cells and thereby reduce the risk of <a href="/wiki/Graft-versus-host_disease" title="Graft-versus-host disease">graft-versus-host disease</a>. Patients may also receive a hormone to stimulate production of red blood cells. These treatments may be <a href="/wiki/Medical_necessity" title="Medical necessity">medically necessary</a>, but do not kill the hairy cells.</p>
<p>Patients with low <a href="/wiki/Neutrophil" title="Neutrophil" class="mw-redirect">neutrophil</a> counts may be given <b><a href="/wiki/Filgrastim" title="Filgrastim">filgrastim</a></b> or a similar hormone to stimulate production of white blood cells. However, a 1999 study indicates that routine administration of this expensive injected drug has no practical value for HCL patients after cladribine administration.<sup id="cite_ref-41" class="reference"><a href="#cite_note-41"><span>[</span>41<span>]</span></a></sup> In this study, patients who received filgrastim were just as likely to experience a high fever and to be admitted to the hospital as those who did not, even though the drug artificially inflated their white blood cell counts. This study leaves open the possibility that filgrastim may still be appropriate for patients who have symptoms of infection, or at times other than shortly after cladribine treatment.</p>
<p>Although hairy cells are technically long-lived, instead of rapidly dividing, some late-stage patients are treated with <b>broad-spectrum chemotherapy agents</b> such as <a href="/wiki/Methotrexate" title="Methotrexate">methotrexate</a> that are effective at killing rapidly dividing cells. This is not typically attempted unless all other options have been exhausted and it is typically unsuccessful.</p>
<h2><span class="mw-headline" id="Prognosis">Prognosis</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Hairy_cell_leukemia&amp;action=edit&amp;section=12" title="Edit section: Prognosis">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<h3><span class="mw-headline" id="Treatment_success">Treatment success</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Hairy_cell_leukemia&amp;action=edit&amp;section=13" title="Edit section: Treatment success">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>More than 95% of new patients are treated well or at least adequately by cladribine or pentostatin.<sup id="cite_ref-42" class="reference"><a href="#cite_note-42"><span>[</span>42<span>]</span></a></sup> A majority of new patients can expect a disease-free remission time span of about ten years, or sometimes much longer after taking one of these drugs just once. If re-treatment is necessary in the future, the drugs are normally effective again, although the average length of remission is somewhat shorter in subsequent treatments.</p>
<p>As with B-cell chronic lymphocytic leukemia, mutations in the <a href="/wiki/IGHV" title="IGHV" class="mw-redirect">IGHV</a> on hairy cells are associated with better responses to initial treatments and with prolonged survival.<sup id="cite_ref-43" class="reference"><a href="#cite_note-43"><span>[</span>43<span>]</span></a></sup></p>
<p>How soon after treatment a patient feels "normal" again depends on several factors, including:</p>
<ul>
<li>how advanced the disease was at the time of treatment;</li>
<li>the patient's underlying health status;</li>
<li>whether the patient had a "complete response" or only a partial response to the treatment;</li>
<li>whether the patient experienced any of the rare, but serious side effects such as kidney failure;</li>
<li>how aggressive the individual's disease is;</li>
<li>whether the patient is experiencing unusual psychological trauma from the "cancer" diagnosis; and</li>
<li>how the patient perceived his or her pre-treatment energy level and daily functioning.</li>
</ul>
<h3><span class="mw-headline" id="Lifespan">Lifespan</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Hairy_cell_leukemia&amp;action=edit&amp;section=14" title="Edit section: Lifespan">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>With appropriate treatment, the overall projected lifespan for patients is normal or near-normal. In all patients, the first two years after diagnosis have the highest risk for fatal outcome; generally, surviving five years predicts good control of the disease. After five years' clinical remission, patients with normal blood counts can often qualify for private life insurance with some companies.<sup id="cite_ref-44" class="reference"><a href="#cite_note-44"><span>[</span>44<span>]</span></a></sup></p>
<p>Accurately measuring survival for patients with the variant form of the disease (HCL-V) is complicated by the relatively high median age (70 years old) at diagnosis. However, HCL-V patients routinely survive for more than 10 years, and younger patients can likely expect a long life.</p>
<p>Worldwide, approximately 300 HCL patients per year are expected to die.<sup id="cite_ref-45" class="reference"><a href="#cite_note-45"><span>[</span>45<span>]</span></a></sup> Some of these patients were diagnosed with HCL due to a serious illness that prevented them from receiving initial treatment in time; many others died after living a normal lifespan and experiencing years of good control of the disease. Perhaps as many as five out of six HCL patients die from some other cause.</p>
<h3><span class="mw-headline" id="Follow-up_care">Follow-up care</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Hairy_cell_leukemia&amp;action=edit&amp;section=15" title="Edit section: Follow-up care">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Despite decade-long remissions and years of living very normal lives after treatment, hairy cell leukemia is officially considered an incurable disease. While survivors of solid tumors are commonly declared to be permanently cured after two, three, or five years, people who have hairy cell leukemia are never considered 'cured'. Relapses of HCL have happened even after more than twenty years of continuous remission. Patients will require lifelong monitoring and should be aware that the disease can recur even after decades of good health.</p>
<p>People in remission need regular follow-up examinations after their treatment is over. Most physicians insist on seeing patients at least once a year for the rest of the patient's life, and getting blood counts about twice a year. Regular follow-up care ensures that patients are carefully monitored, any changes in health are discussed, and new or recurrent cancer can be detected and treated as soon as possible. Between regularly scheduled appointments, people who have hairy cell leukemia should report any health problems, especially viral or bacterial infections, as soon as they appear.</p>
<p>HCL patients are also at a slightly higher than average risk for developing a second kind of cancer, such as colon cancer or lung cancer, at some point during their lives (including before their HCL diagnosis). This appears to relate best to the number of hairy cells, and not to different forms of treatment.<sup id="cite_ref-46" class="reference"><a href="#cite_note-46"><span>[</span>46<span>]</span></a></sup> On average, patients might reasonably expect to have as much as double the risk of developing another cancer, with a peak about two years after HCL diagnosis and falling steadily after that, assuming that the HCL was successfully treated. Aggressive surveillance and prevention efforts are generally warranted, although the lifetime odds of developing a second cancer after HCL diagnosis are still less than 50%.</p>
<p>There is also a higher risk of developing an <a href="/wiki/Autoimmune_disease" title="Autoimmune disease">autoimmune disease</a>.<sup id="cite_ref-Wintrobe_23-14" class="reference"><a href="#cite_note-Wintrobe-23"><span>[</span>23<span>]</span></a></sup> Autoimmune diseases may also go into remission after treatment of HCL.<sup id="cite_ref-Wintrobe_23-15" class="reference"><a href="#cite_note-Wintrobe-23"><span>[</span>23<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Prevention.2FScreening">Prevention/Screening</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Hairy_cell_leukemia&amp;action=edit&amp;section=16" title="Edit section: Prevention/Screening">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Because the cause is unknown, no effective preventive measures can be taken.</p>
<p>Because the disease is rare, routine screening is not cost-effective.</p>
<h2><span class="mw-headline" id="Epidemiology">Epidemiology</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Hairy_cell_leukemia&amp;action=edit&amp;section=17" title="Edit section: Epidemiology">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>This disease is rare, with fewer than 1 in 10,000 people being diagnosed with HCL during their lives. Men are four to five times more likely to develop hairy cell leukemia than women.<sup id="cite_ref-47" class="reference"><a href="#cite_note-47"><span>[</span>47<span>]</span></a></sup> In the United States, the annual <a href="/wiki/Incidence_(epidemiology)" title="Incidence (epidemiology)">incidence</a> is approximately 3 cases per 1,000,000 men each year, and 0.6 cases per 1,000,000 women each year.<sup id="cite_ref-Wintrobe_23-16" class="reference"><a href="#cite_note-Wintrobe-23"><span>[</span>23<span>]</span></a></sup></p>
<p>Most patients are white males over the age of 50,<sup id="cite_ref-Wintrobe_23-17" class="reference"><a href="#cite_note-Wintrobe-23"><span>[</span>23<span>]</span></a></sup> although it has been diagnosed in at least one teenager.<sup id="cite_ref-pmid11554237_48-0" class="reference"><a href="#cite_note-pmid11554237-48"><span>[</span>48<span>]</span></a></sup> It is less common in people of African and Asian descent compared to people of European descent.</p>
<p>It does not appear to be hereditary, although occasional familial cases that suggest a predisposition have been reported,<sup id="cite_ref-49" class="reference"><a href="#cite_note-49"><span>[</span>49<span>]</span></a></sup> usually showing a common <a href="/wiki/Human_Leukocyte_Antigen" title="Human Leukocyte Antigen" class="mw-redirect">Human Leukocyte Antigen</a> (HLA) type.<sup id="cite_ref-Wintrobe_23-18" class="reference"><a href="#cite_note-Wintrobe-23"><span>[</span>23<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Research_directions">Research directions</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Hairy_cell_leukemia&amp;action=edit&amp;section=18" title="Edit section: Research directions">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>The Hairy Cell Leukemia Consortium was founded in 2008 to address researchers' concerns about the long-term future of research on the disease.<sup id="cite_ref-pmid19276454_50-0" class="reference"><a href="#cite_note-pmid19276454-50"><span>[</span>50<span>]</span></a></sup> Partly because existing treatments are so successful, the field has attracted very few new researchers.</p>
<p>In 2013 the Hairy Cell Leukemia Foundation was created when the Hairy Cell Leukemia Consortium and the Hairy Cell Leukemia Research Foundation joined together. The HCLF is dedicated to improving outcomes for patients by advancing research into the causes and treatment of hairy cell leukemia, as well as by providing educational resources and comfort to all those affected by hairy cell leukemia.<sup id="cite_ref-51" class="reference"><a href="#cite_note-51"><span>[</span>51<span>]</span></a></sup></p>
<p>Three immunotoxin drugs have been studied in patients at the <a href="/wiki/NIH" title="NIH" class="mw-redirect">NIH</a><a href="/wiki/National_Cancer_Institute" title="National Cancer Institute">National Cancer Institute</a> in the U.S.: <a href="/wiki/BL22" title="BL22" class="mw-redirect">BL22</a>,<sup id="cite_ref-52" class="reference"><a href="#cite_note-52"><span>[</span>52<span>]</span></a></sup> <a href="/wiki/HA22" title="HA22" class="mw-redirect">HA22</a><sup id="cite_ref-53" class="reference"><a href="#cite_note-53"><span>[</span>53<span>]</span></a></sup> and <a href="/w/index.php?title=LMB-2&amp;action=edit&amp;redlink=1" class="new" title="LMB-2 (page does not exist)">LMB-2</a>.<sup id="cite_ref-54" class="reference"><a href="#cite_note-54"><span>[</span>54<span>]</span></a></sup> All of these protein-based drugs combine part of an anti-B cell antibody with a bacterial toxin to kill the cells on internalization. BL22 and HA22 attack a common protein called CD22, which is present on hairy cells and healthy B cells. LMB-2 attacks a protein called CD25, which is not present in HCL-variant, so LMB-2 is only useful for patients with HCL-classic or the Japanese variant. HA-22, now renamed moxetumab pasudotox, is being studied in patients with relapsed hairy cell leukemia at the National Cancer Institute in Bethesda, Maryland, MD Anderson Cancer Center in Houston, Texas, and Ohio State University in Columbus, Ohio. Other sites for the study are expected to start accepting patients in late 2014, including The Royal Marsden Hospital in London, England.<a rel="nofollow" class="external autonumber" href="http://clinicaltrials.gov/ct2/show/NCT01829711?term=Hairy+cell+leukemia&amp;rank=14">[1]</a></p>
<p>Other clinical trials<sup id="cite_ref-55" class="reference"><a href="#cite_note-55"><span>[</span>55<span>]</span></a></sup> are studying the effectiveness of cladribine followed by rituximab in eliminating <a href="/wiki/Minimal_residual_disease" title="Minimal residual disease">residual hairy cells</a> that remain after treatment by cladribine or pentostatin. It is not currently known if the elimination of such residual cells will result in more durable remissions.</p>
<p>BRAF mutation has been frequently detected in HCL (Tiacci et al. NEJM 2011) and some patients may respond to Vemurafenib</p>
<p>The major remaining research questions are identifying the cause of HCL and determining what prevents hairy cells from maturing normally.<sup id="cite_ref-56" class="reference"><a href="#cite_note-56"><span>[</span>56<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="See_also">See also</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Hairy_cell_leukemia&amp;action=edit&amp;section=19" title="Edit section: See also">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul>
<li><a href="/wiki/Annexin_A1" title="Annexin A1">Annexin A1</a></li>
<li><a href="/wiki/List_of_cutaneous_conditions" title="List of cutaneous conditions">List of cutaneous conditions</a></li>
</ul>
<h2><span class="mw-headline" id="References">References</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Hairy_cell_leukemia&amp;action=edit&amp;section=20" title="Edit section: References">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="reflist columns references-column-count references-column-count-2" style="-moz-column-count: 2; -webkit-column-count: 2; column-count: 2; list-style-type: decimal;">
<ol class="references">
<li id="cite_note-1"><span class="mw-cite-backlink"><b><a href="#cite_ref-1">^</a></b></span> <span class="reference-text"><span class="citation journal">Schrek R, Donnelly WJ (February 1966). <a rel="nofollow" class="external text" href="http://bloodjournal.hematologylibrary.org/cgi/content/abstract/27/2/199">"<span style="padding-left:0.2em;">"</span>Hairy" cells in blood in lymphoreticular neoplastic disease and "flagellated" cells of normal lymph nodes"</a>. <i>Blood</i> <b>27</b> (2): 199–211. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/5322749">5322749</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=%22Hairy%22+cells+in+blood+in+lymphoreticular+neoplastic+disease+and+%22flagellated%22+cells+of+normal+lymph+nodes&amp;rft.au=Donnelly%2C+WJ&amp;rft.aufirst=R&amp;rft.aulast=Schrek&amp;rft.au=Schrek%2C+R&amp;rft.date=February+1966&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcgi%2Fcontent%2Fabstract%2F27%2F2%2F199&amp;rft_id=info%3Apmid%2F5322749&amp;rft.issue=2&amp;rft.jtitle=Blood&amp;rft.pages=199-211&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=27" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-urlAmerican_Journal_of_Clinical_Pathology-2"><span class="mw-cite-backlink"><b><a href="#cite_ref-urlAmerican_Journal_of_Clinical_Pathology_2-0">^</a></b></span> <span class="reference-text"><span class="citation journal"><a rel="nofollow" class="external text" href="http://ajcp.metapress.com/link.asp?id=8qytyq1clqmhq9cl">"American Journal of Clinical Pathology"</a><span class="reference-accessdate">. Retrieved <span class="nowrap">2009-01-31</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.btitle=American+Journal+of+Clinical+Pathology&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fajcp.metapress.com%2Flink.asp%3Fid%3D8qytyq1clqmhq9cl&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-bloodjournal.hematologylibrary.org-3"><span class="mw-cite-backlink">^ <a href="#cite_ref-bloodjournal.hematologylibrary.org_3-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-bloodjournal.hematologylibrary.org_3-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Sainati L, Matutes E, Mulligan S, de Oliveira MP, Rani S, Lampert IA et al. (July 1990). <a rel="nofollow" class="external text" href="http://www.bloodjournal.org/cgi/pmidlookup?view=long&amp;pmid=2364167">"A variant form of hairy cell leukemia resistant to <i>alpha</i>-interferon: clinical and phenotypic characteristics of 17 patients"</a>. <i>Blood</i> <b>76</b> (1): 157–62. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/2364167">2364167</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=A+variant+form+of+hairy+cell+leukemia+resistant+to+alpha-interferon%3A+clinical+and+phenotypic+characteristics+of+17+patients&amp;rft.au=Catovsky%2C+D&amp;rft.au=de+Oliveira%2C+MP&amp;rft.aufirst=L&amp;rft.au=Lampert%2C+IA&amp;rft.aulast=Sainati&amp;rft.au=Matutes%2C+E&amp;rft.au=Mulligan%2C+S&amp;rft.au=Rani%2C+S&amp;rft.au=Sainati%2C+L&amp;rft.date=July+1990&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.bloodjournal.org%2Fcgi%2Fpmidlookup%3Fview%3Dlong%26pmid%3D2364167&amp;rft_id=info%3Apmid%2F2364167&amp;rft.issue=1&amp;rft.jtitle=Blood&amp;rft.pages=157-62&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=76" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid7206776-4"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid7206776_4-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Cawley JC, Burns GF, Hayhoe FG (1980). "A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia". <i>Leuk. Res.</i> <b>4</b> (6): 547–59. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2F0145-2126%2880%2990066-1">10.1016/0145-2126(80)90066-1</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/7206776">7206776</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=A+chronic+lymphoproliferative+disorder+with+distinctive+features%3A+a+distinct+variant+of+hairy-cell+leukaemia&amp;rft.au=Burns%2C+GF&amp;rft.au=Cawley%2C+JC&amp;rft.aufirst=JC&amp;rft.au=Hayhoe%2C+FG&amp;rft.aulast=Cawley&amp;rft.date=1980&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2F0145-2126%2880%2990066-1&amp;rft_id=info%3Apmid%2F7206776&amp;rft.issue=6&amp;rft.jtitle=Leuk.+Res.&amp;rft.pages=547-59&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=4" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid11243388-5"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid11243388_5-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid11243388_5-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid11243388_5-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-pmid11243388_5-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Matutes E, Wotherspoon A, Brito-Babapulle V, Catovsky D (2001). "The natural history and clinico-pathological features of the variant form of hairy cell leukemia". <i>Leukemia</i> <b>15</b> (1): 184–6. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fsj.leu.2401999">10.1038/sj.leu.2401999</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11243388">11243388</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=The+natural+history+and+clinico-pathological+features+of+the+variant+form+of+hairy+cell+leukemia&amp;rft.au=Brito-Babapulle%2C+V&amp;rft.au=Catovsky%2C+D&amp;rft.aufirst=E&amp;rft.aulast=Matutes&amp;rft.au=Matutes%2C+E&amp;rft.au=Wotherspoon%2C+A&amp;rft.date=2001&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fsj.leu.2401999&amp;rft_id=info%3Apmid%2F11243388&amp;rft.issue=1&amp;rft.jtitle=Leukemia&amp;rft.pages=184-6&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=15" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid15737038-6"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid15737038_6-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Ya-In C, Brandwein J, Pantalony D, Chang H (2005). "Hairy cell leukemia variant with features of intrasinusoidal bone marrow involvement". <i>Arch. Pathol. Lab. Med.</i> <b>129</b> (3): 395–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:10.1043/1543-2165(2005)129&lt;395:HCLVWF&gt;2.0.CO;2 (inactive 2015-01-13). <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15737038">15737038</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Hairy+cell+leukemia+variant+with+features+of+intrasinusoidal+bone+marrow+involvement&amp;rft.au=Brandwein%2C+J&amp;rft.au=Chang%2C+H&amp;rft.aufirst=C&amp;rft.aulast=Ya-In&amp;rft.au=Pantalony%2C+D&amp;rft.au=Ya-In%2C+C&amp;rft.date=2005&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1043%2F1543-2165%282005%29129%3C395%3AHCLVWF%3E2.0.CO%3B2&amp;rft_id=info%3Apmid%2F15737038&amp;rft.issue=3&amp;rft.jtitle=Arch.+Pathol.+Lab.+Med.&amp;rft.pages=395-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=129" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-7"><span class="mw-cite-backlink"><b><a href="#cite_ref-7">^</a></b></span> <span class="reference-text"><span class="citation journal">Burthem J, Cawley JC (January 1994). <a rel="nofollow" class="external text" href="http://www.bloodjournal.org/cgi/pmidlookup?view=long&amp;pmid=8286747">"The bone marrow fibrosis of hairy-cell leukemia is caused by the synthesis and assembly of a fibronectin matrix by the hairy cells"</a>. <i>Blood</i> <b>83</b> (2): 497–504. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/8286747">8286747</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=The+bone+marrow+fibrosis+of+hairy-cell+leukemia+is+caused+by+the+synthesis+and+assembly+of+a+fibronectin+matrix+by+the+hairy+cells&amp;rft.au=Burthem%2C+J&amp;rft.au=Cawley%2C+JC&amp;rft.aufirst=J&amp;rft.aulast=Burthem&amp;rft.date=January+1994&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.bloodjournal.org%2Fcgi%2Fpmidlookup%3Fview%3Dlong%26pmid%3D8286747&amp;rft_id=info%3Apmid%2F8286747&amp;rft.issue=2&amp;rft.jtitle=Blood&amp;rft.pages=497-504&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=83" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-8"><span class="mw-cite-backlink"><b><a href="#cite_ref-8">^</a></b></span> <span class="reference-text"><span class="citation journal">de Totero D, Tazzari PL, Lauria F, Raspadori D, di Celle PF, Carbone A et al. (July 1993). <a rel="nofollow" class="external text" href="http://www.bloodjournal.org/cgi/pmidlookup?view=long&amp;pmid=8329708">"Phenotypic analysis of hairy cell leukemia: "variant" cases express the interleukin-2 receptor <i>beta</i> chain, but not the <i>alpha</i> chain (CD25)"</a>. <i>Blood</i> <b>82</b> (2): 528–35. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/8329708">8329708</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Phenotypic+analysis+of+hairy+cell+leukemia%3A+%22variant%22+cases+express+the+interleukin-2+receptor+beta+chain%2C+but+not+the+alpha+chain+%28CD25%29&amp;rft.au=Carbone%2C+A&amp;rft.au=de+Totero%2C+D&amp;rft.au=di+Celle%2C+PF&amp;rft.aufirst=D&amp;rft.au=Foa%2C+R&amp;rft.au=Gobbi%2C+M&amp;rft.aulast=de+Totero&amp;rft.au=Lauria%2C+F&amp;rft.au=Raspadori%2C+D&amp;rft.au=Tazzari%2C+PL&amp;rft.date=July+1993&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.bloodjournal.org%2Fcgi%2Fpmidlookup%3Fview%3Dlong%26pmid%3D8329708&amp;rft_id=info%3Apmid%2F8329708&amp;rft.issue=2&amp;rft.jtitle=Blood&amp;rft.pages=528-35&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=82" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid12670464-9"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid12670464_9-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Matutes E, Wotherspoon A, Catovsky D (2003). "The variant form of hairy-cell leukaemia". <i>Best Pract Res Clin Haematol</i> <b>16</b> (1): 41–56. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS1521-6926%2802%2900086-5">10.1016/S1521-6926(02)00086-5</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12670464">12670464</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=The+variant+form+of+hairy-cell+leukaemia&amp;rft.au=Catovsky%2C+D&amp;rft.aufirst=E&amp;rft.aulast=Matutes&amp;rft.au=Matutes%2C+E&amp;rft.au=Wotherspoon%2C+A&amp;rft.date=2003&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS1521-6926%2802%2900086-5&amp;rft_id=info%3Apmid%2F12670464&amp;rft.issue=1&amp;rft.jtitle=Best+Pract+Res+Clin+Haematol&amp;rft.pages=41-56&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=16" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid10576509-10"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid10576509_10-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Vallianatou K, Brito-Babapulle V, Matutes E, Atkinson S, Catovsky D (1999). "p53 gene deletion and trisomy 12 in hairy cell leukemia and its variant". <i>Leuk. Res.</i> <b>23</b> (11): 1041–5. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS0145-2126%2899%2900127-7">10.1016/S0145-2126(99)00127-7</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10576509">10576509</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=p53+gene+deletion+and+trisomy+12+in+hairy+cell+leukemia+and+its+variant&amp;rft.au=Atkinson%2C+S&amp;rft.au=Brito-Babapulle%2C+V&amp;rft.au=Catovsky%2C+D&amp;rft.aufirst=K&amp;rft.aulast=Vallianatou&amp;rft.au=Matutes%2C+E&amp;rft.au=Vallianatou%2C+K&amp;rft.date=1999&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS0145-2126%2899%2900127-7&amp;rft_id=info%3Apmid%2F10576509&amp;rft.issue=11&amp;rft.jtitle=Leuk.+Res.&amp;rft.pages=1041-5&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=23" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid15199752-11"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid15199752_11-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Miyazaki M, Taguchi A, Sakuragi S, Mitani N, Matsuda K, Shinohara K (May 2004). "[Hairy cell leukemia, Japanese variant, successfully treated with cladribine]". <i>Rinsho Ketsueki</i> (in Japanese) <b>45</b> (5): 405–7. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15199752">15199752</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=%5BHairy+cell+leukemia%2C+Japanese+variant%2C+successfully+treated+with+cladribine%5D&amp;rft.aufirst=M&amp;rft.aulast=Miyazaki&amp;rft.au=Matsuda%2C+K&amp;rft.au=Mitani%2C+N&amp;rft.au=Miyazaki%2C+M&amp;rft.au=Sakuragi%2C+S&amp;rft.au=Shinohara%2C+K&amp;rft.au=Taguchi%2C+A&amp;rft.date=May+2004&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F15199752&amp;rft.issue=5&amp;rft.jtitle=Rinsho+Ketsueki&amp;rft.pages=405-7&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=45" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-12"><span class="mw-cite-backlink"><b><a href="#cite_ref-12">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cancer.gov/cancerinfo/pdq/treatment/hairy-cell-leukemia/patient#Keypoint3">"Hairy Cell Leukemia Treatment"</a>. <a href="/wiki/National_Cancer_Institute" title="National Cancer Institute">National Cancer Institute</a><span class="reference-accessdate">. Retrieved <span class="nowrap">2007-09-07</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.btitle=Hairy+Cell+Leukemia+Treatment&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.cancer.gov%2Fcancerinfo%2Fpdq%2Ftreatment%2Fhairy-cell-leukemia%2Fpatient%23Keypoint3&amp;rft.pub=National+Cancer+Institute&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid512041-13"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid512041_13-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Zuzel M, Cawley JC, Paton RC, Burns GF, McNicol GP (1979). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1145815">"Platelet function in hairy-cell leukaemia"</a>. <i>J. Clin. Pathol.</i> <b>32</b> (8): 814–21. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1136%2Fjcp.32.8.814">10.1136/jcp.32.8.814</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1145815">1145815</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/512041">512041</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Platelet+function+in+hairy-cell+leukaemia&amp;rft.au=Burns%2C+GF&amp;rft.au=Cawley%2C+JC&amp;rft.aufirst=M&amp;rft.aulast=Zuzel&amp;rft.au=McNicol%2C+GP&amp;rft.au=Paton%2C+RC&amp;rft.au=Zuzel%2C+M&amp;rft.date=1979&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1145815&amp;rft_id=info%3Adoi%2F10.1136%2Fjcp.32.8.814&amp;rft_id=info%3Apmc%2F1145815&amp;rft_id=info%3Apmid%2F512041&amp;rft.issue=8&amp;rft.jtitle=J.+Clin.+Pathol.&amp;rft.pages=814-21&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=32" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-14"><span class="mw-cite-backlink"><b><a href="#cite_ref-14">^</a></b></span> <span class="reference-text"><span class="citation journal">Pandolfino J, Hakimian D, Rademaker AW, Tallman MS (July 1997). "Hypocholesterolemia in hairy cell leukemia: a marker for proliferative activity". <i>Am. J. Hematol.</i> <b>55</b> (3): 129–33. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1002%2F%28SICI%291096-8652%28199707%2955%3A3%3C129%3A%3AAID-AJH2%3E3.0.CO%3B2-U">10.1002/(SICI)1096-8652(199707)55:3&lt;129::AID-AJH2&gt;3.0.CO;2-U</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/9256291">9256291</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Hypocholesterolemia+in+hairy+cell+leukemia%3A+a+marker+for+proliferative+activity&amp;rft.aufirst=J&amp;rft.au=Hakimian%2C+D&amp;rft.aulast=Pandolfino&amp;rft.au=Pandolfino%2C+J&amp;rft.au=Rademaker%2C+AW&amp;rft.au=Tallman%2C+MS&amp;rft.date=July+1997&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F%28SICI%291096-8652%28199707%2955%3A3%3C129%3A%3AAID-AJH2%3E3.0.CO%3B2-U&amp;rft_id=info%3Apmid%2F9256291&amp;rft.issue=3&amp;rft.jtitle=Am.+J.+Hematol.&amp;rft.pages=129-33&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=55" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-15"><span class="mw-cite-backlink"><b><a href="#cite_ref-15">^</a></b></span> <span class="reference-text"><span class="citation journal">Juliusson G, Vitols S, Liliemark J (July 1995). <a rel="nofollow" class="external text" href="http://www.bmj.com/cgi/content/full/311/6996/27">"Mechanisms behind hypocholesterolaemia in hairy cell leukaemia"</a>. <i>BMJ</i> <b>311</b> (6996): 27. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1136%2Fbmj.311.6996.27">10.1136/bmj.311.6996.27</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2550084">2550084</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/7613319">7613319</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Mechanisms+behind+hypocholesterolaemia+in+hairy+cell+leukaemia&amp;rft.aufirst=G&amp;rft.au=Juliusson%2C+G&amp;rft.aulast=Juliusson&amp;rft.au=Liliemark%2C+J&amp;rft.au=Vitols%2C+S&amp;rft.date=July+1995&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.bmj.com%2Fcgi%2Fcontent%2Ffull%2F311%2F6996%2F27&amp;rft_id=info%3Adoi%2F10.1136%2Fbmj.311.6996.27&amp;rft_id=info%3Apmc%2F2550084&amp;rft_id=info%3Apmid%2F7613319&amp;rft.issue=6996&amp;rft.jtitle=BMJ&amp;rft.pages=27&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=311" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid7577624-16"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid7577624_16-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Clavel J, Mandereau L, Cordier S, Le Goaster C, Hémon D, Conso F et al. (1995). "Hairy cell leukaemia, occupation, and smoking". <i>Br. J. Haematol.</i> <b>91</b> (1): 154–61. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1111%2Fj.1365-2141.1995.tb05261.x">10.1111/j.1365-2141.1995.tb05261.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/7577624">7577624</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Hairy+cell+leukaemia%2C+occupation%2C+and+smoking&amp;rft.au=Clavel%2C+J&amp;rft.au=Conso%2C+F&amp;rft.au=Cordier%2C+S&amp;rft.aufirst=J&amp;rft.au=Flandrin%2C+G&amp;rft.au=H%C3%A9mon%2C+D&amp;rft.aulast=Clavel&amp;rft.au=Le+Goaster%2C+C&amp;rft.au=Mandereau%2C+L&amp;rft.date=1995&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1365-2141.1995.tb05261.x&amp;rft_id=info%3Apmid%2F7577624&amp;rft.issue=1&amp;rft.jtitle=Br.+J.+Haematol.&amp;rft.pages=154-61&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=91" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid11083509-17"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid11083509_17-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Orlandi G, Fanucchi S, Strata G, Pataleo L, Landucci Pellegrini L, Prontera C et al. (2000). "Transient autonomic nervous system dysfunction during hyperacute stroke". <i>Acta Neurol. Scand.</i> <b>102</b> (5): 317–21. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1034%2Fj.1600-0404.2000.102005317.x">10.1034/j.1600-0404.2000.102005317.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11083509">11083509</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Transient+autonomic+nervous+system+dysfunction+during+hyperacute+stroke&amp;rft.au=Fanucchi%2C+S&amp;rft.aufirst=G&amp;rft.au=Landucci+Pellegrini%2C+L&amp;rft.aulast=Orlandi&amp;rft.au=Martini%2C+A&amp;rft.au=Murri%2C+L&amp;rft.au=Orlandi%2C+G&amp;rft.au=Pataleo%2C+L&amp;rft.au=Prontera%2C+C&amp;rft.au=Strata%2C+G&amp;rft.date=2000&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1034%2Fj.1600-0404.2000.102005317.x&amp;rft_id=info%3Apmid%2F11083509&amp;rft.issue=5&amp;rft.jtitle=Acta+Neurol.+Scand.&amp;rft.pages=317-21&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=102" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid21663470-18"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid21663470_18-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP et al. (2011). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3689585">"BRAFMutations in Hairy-Cell Leukemia"</a>. <i>N Engl J Med.</i> <b>364</b> (24): 2305–2315. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1056%2FNEJMoa1014209">10.1056/NEJMoa1014209</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3689585">3689585</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21663470">21663470</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=BRAFMutations+in+Hairy-Cell+Leukemia&amp;rft.au=Ambrosetti%2C+A&amp;rft.au=Arcaini%2C+L&amp;rft.au=Bigerna%2C+B&amp;rft.au=Capponi%2C+M&amp;rft.au=Di+Raimondo%2C+F&amp;rft.au=Elliott%2C+O&amp;rft.au=Falini%2C+B&amp;rft.au=Farinelli%2C+L&amp;rft.aufirst=E&amp;rft.au=Fo%C3%A0%2C+R&amp;rft.au=Forconi%2C+F&amp;rft.au=Haferlach%2C+C&amp;rft.au=Haferlach%2C+T&amp;rft.au=Holmes%2C+A&amp;rft.au=Inghirami%2C+G&amp;rft.au=Kern%2C+W&amp;rft.aulast=Tiacci&amp;rft.au=Liso%2C+A&amp;rft.au=Mannucci%2C+R&amp;rft.au=Martelli%2C+MP&amp;rft.au=Musto%2C+P&amp;rft.au=Pacini%2C+R&amp;rft.au=Pasqualucci%2C+L&amp;rft.au=Patti%2C+C&amp;rft.au=Pettirossi%2C+V&amp;rft.au=Pileri%2C+S&amp;rft.au=Pizzolo%2C+G&amp;rft.au=Pucciarini%2C+A&amp;rft.au=Pulsoni%2C+A&amp;rft.au=Rabadan%2C+R&amp;rft.au=Schiavoni%2C+G&amp;rft.au=Schnittger%2C+S&amp;rft.au=Semenzato%2C+G&amp;rft.au=Sportoletti%2C+P&amp;rft.au=Tiacci%2C+E&amp;rft.au=Trentin%2C+L&amp;rft.au=Trifonov%2C+V&amp;rft.au=Wells%2C+VA&amp;rft.date=2011&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3689585&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMoa1014209&amp;rft_id=info%3Apmc%2F3689585&amp;rft_id=info%3Apmid%2F21663470&amp;rft.issue=24&amp;rft.jtitle=N+Engl+J+Med.&amp;rft.pages=2305-2315&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=364" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-19"><span class="mw-cite-backlink"><b><a href="#cite_ref-19">^</a></b></span> <span class="reference-text"><span class="citation book">Committee to Review the Health Effects in Vietnam Veterans of Exposure to Herbicides (Seventh Biennial Update) (2009). <a rel="nofollow" class="external text" href="http://www.nap.edu/catalog.php?record_id=12662"><i>Veterans and Agent Orange: Update 2008</i></a>. Institute of Medicine. pp.&#160;349–350. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/978-0-309-13884-0" title="Special:BookSources/978-0-309-13884-0">978-0-309-13884-0</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.au=Committee+to+Review+the+Health+Effects+in+Vietnam+Veterans+of+Exposure+to+Herbicides+%28Seventh+Biennial+Update%29&amp;rft.aulast=Committee+to+Review+the+Health+Effects+in+Vietnam+Veterans+of+Exposure+to+Herbicides+%28Seventh+Biennial+Update%29&amp;rft.btitle=Veterans+and+Agent+Orange%3A+Update+2008&amp;rft.date=2009&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.nap.edu%2Fcatalog.php%3Frecord_id%3D12662&amp;rft.isbn=978-0-309-13884-0&amp;rft.pages=349-350&amp;rft.pub=Institute+of+Medicine&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid16155606-20"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid16155606_20-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Feuer G, Green PL (September 2005). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2659530">"Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2"</a>. <i>Oncogene</i> <b>24</b> (39): 5996–6004. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fsj.onc.1208971">10.1038/sj.onc.1208971</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2659530">2659530</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16155606">16155606</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Comparative+biology+of+human+T-cell+lymphotropic+virus+type+1+%28HTLV-1%29+and+HTLV-2&amp;rft.au=Feuer%2C+G&amp;rft.aufirst=G&amp;rft.au=Green%2C+PL&amp;rft.aulast=Feuer&amp;rft.date=September+2005&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2659530&amp;rft_id=info%3Adoi%2F10.1038%2Fsj.onc.1208971&amp;rft_id=info%3Apmc%2F2659530&amp;rft_id=info%3Apmid%2F16155606&amp;rft.issue=39&amp;rft.jtitle=Oncogene&amp;rft.pages=5996-6004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=24" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid2827811-21"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid2827811_21-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Rosenblatt JD, Giorgi JV, Golde DW, Ezra JB, Wu A, Winberg CD et al. (February 1988). <a rel="nofollow" class="external text" href="http://www.bloodjournal.org/cgi/pmidlookup?view=long&amp;pmid=2827811">"Integrated human T-cell leukemia virus II genome in CD8 + T cells from a patient with "atypical" hairy cell leukemia: evidence for distinct T and B cell lymphoproliferative disorders"</a>. <i>Blood</i> <b>71</b> (2): 363–9. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/2827811">2827811</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Integrated+human+T-cell+leukemia+virus+II+genome+in+CD8+%2B+T+cells+from+a+patient+with+%22atypical%22+hairy+cell+leukemia%3A+evidence+for+distinct+T+and+B+cell+lymphoproliferative+disorders&amp;rft.au=Chen%2C+IS&amp;rft.au=Ezra%2C+JB&amp;rft.aufirst=JD&amp;rft.au=Giorgi%2C+JV&amp;rft.au=Glaspy%2C+J&amp;rft.au=Golde%2C+DW&amp;rft.aulast=Rosenblatt&amp;rft.au=Rosenblatt%2C+JD&amp;rft.au=Wachsman%2C+W&amp;rft.au=Winberg%2C+CD&amp;rft.au=Wu%2C+A&amp;rft.date=February+1988&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.bloodjournal.org%2Fcgi%2Fpmidlookup%3Fview%3Dlong%26pmid%3D2827811&amp;rft_id=info%3Apmid%2F2827811&amp;rft.issue=2&amp;rft.jtitle=Blood&amp;rft.pages=363-9&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=71" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid15595431-22"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid15595431_22-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Roucoux DF, Murphy EL (2004). "The epidemiology and disease outcomes of human T-lymphotropic virus type II". <i>AIDS Rev</i> <b>6</b> (3): 144–54. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15595431">15595431</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=The+epidemiology+and+disease+outcomes+of+human+T-lymphotropic+virus+type+II&amp;rft.aufirst=DF&amp;rft.aulast=Roucoux&amp;rft.au=Murphy%2C+EL&amp;rft.au=Roucoux%2C+DF&amp;rft.date=2004&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F15595431&amp;rft.issue=3&amp;rft.jtitle=AIDS+Rev&amp;rft.pages=144-54&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=6" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Wintrobe-23"><span class="mw-cite-backlink">^ <a href="#cite_ref-Wintrobe_23-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Wintrobe_23-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Wintrobe_23-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Wintrobe_23-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Wintrobe_23-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Wintrobe_23-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Wintrobe_23-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-Wintrobe_23-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-Wintrobe_23-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-Wintrobe_23-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-Wintrobe_23-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-Wintrobe_23-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-Wintrobe_23-12"><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-Wintrobe_23-13"><sup><i><b>n</b></i></sup></a> <a href="#cite_ref-Wintrobe_23-14"><sup><i><b>o</b></i></sup></a> <a href="#cite_ref-Wintrobe_23-15"><sup><i><b>p</b></i></sup></a> <a href="#cite_ref-Wintrobe_23-16"><sup><i><b>q</b></i></sup></a> <a href="#cite_ref-Wintrobe_23-17"><sup><i><b>r</b></i></sup></a> <a href="#cite_ref-Wintrobe_23-18"><sup><i><b>s</b></i></sup></a></span> <span class="reference-text"><span class="citation book"><a href="/wiki/Maxwell_Wintrobe" title="Maxwell Wintrobe">Wintrobe, Maxwell Myer</a> (2004). <i>Wintrobe's clinical hematology</i>. John G. Greer; John Foerster, John N. Lukens, George M Rodgers, Frixos Paraskevas (11 ed.). Hagerstown, MD: Lippincott Williams &amp; Wilkins. pp.&#160;2465–2466. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/0-7817-3650-1" title="Special:BookSources/0-7817-3650-1">0-7817-3650-1</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.aulast=Wintrobe%2C+Maxwell+Myer&amp;rft.au=Wintrobe%2C+Maxwell+Myer&amp;rft.btitle=Wintrobe%27s+clinical+hematology&amp;rft.date=2004&amp;rft.edition=11&amp;rft.genre=book&amp;rft.isbn=0-7817-3650-1&amp;rft.pages=2465-2466&amp;rft.place=Hagerstown%2C+MD&amp;rft.pub=Lippincott+Williams+%26+Wilkins&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-24"><span class="mw-cite-backlink"><b><a href="#cite_ref-24">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.flowcases.org/casebuilder/index.cfm?fuseaction=displayCase2&amp;caseID=54">"Clinical Flow Cytometry Case #54"</a><span class="reference-accessdate">. Retrieved <span class="nowrap">2007-09-07</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.btitle=Clinical+Flow+Cytometry+Case+%2354&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.flowcases.org%2Fcasebuilder%2Findex.cfm%3Ffuseaction%3DdisplayCase2%26caseID%3D54&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid18798068-25"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid18798068_25-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Cannon T, Mobarek D, Wegge J, Tabbara IA (October 2008). "Hairy cell leukemia: current concepts". <i>Cancer Invest.</i> <b>26</b> (8): 860–5. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1080%2F07357900801965034">10.1080/07357900801965034</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18798068">18798068</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Hairy+cell+leukemia%3A+current+concepts&amp;rft.au=Cannon%2C+T&amp;rft.aufirst=T&amp;rft.aulast=Cannon&amp;rft.au=Mobarek%2C+D&amp;rft.au=Tabbara%2C+IA&amp;rft.au=Wegge%2C+J&amp;rft.date=October+2008&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1080%2F07357900801965034&amp;rft_id=info%3Apmid%2F18798068&amp;rft.issue=8&amp;rft.jtitle=Cancer+Invest.&amp;rft.pages=860-5&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=26" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid16880237-26"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid16880237_26-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid16880237_26-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid16880237_26-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Wanko SO, de Castro C (2006). <a rel="nofollow" class="external text" href="http://theoncologist.alphamedpress.org/cgi/content/full/11/7/780">"Hairy cell leukemia: an elusive but treatable disease"</a>. <i><a href="/wiki/Oncologist" title="Oncologist" class="mw-redirect">Oncologist</a></i> <b>11</b> (7): 780–9. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1634%2Ftheoncologist.11-7-780">10.1634/theoncologist.11-7-780</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16880237">16880237</a>. <q><a rel="nofollow" class="external text" href="http://theoncologist.alphamedpress.org/content/11/7/780/T4.large.jpg"><br />
Table 4. Phenotypic differential diagnosis of hairy cell leukemia</a></q></span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Hairy+cell+leukemia%3A+an+elusive+but+treatable+disease&amp;rft.au=de+Castro%2C+C&amp;rft.aufirst=SO&amp;rft.aulast=Wanko&amp;rft.au=Wanko%2C+SO&amp;rft.date=2006&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Ftheoncologist.alphamedpress.org%2Fcgi%2Fcontent%2Ffull%2F11%2F7%2F780&amp;rft_id=info%3Adoi%2F10.1634%2Ftheoncologist.11-7-780&amp;rft_id=info%3Apmid%2F16880237&amp;rft.issue=7&amp;rft.jtitle=Oncologist&amp;rft.pages=780-9&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=11" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-27"><span class="mw-cite-backlink"><b><a href="#cite_ref-27">^</a></b></span> <span class="reference-text"><i><a rel="nofollow" class="external text" href="http://www.emedicine.com/med/topic937.htm#section~Differentials">Hairy Cell Leukemia~Differentials</a></i> at <a href="/wiki/EMedicine" title="EMedicine">eMedicine</a></span></li>
<li id="cite_note-TiacciTrifonov2011-28"><span class="mw-cite-backlink"><b><a href="#cite_ref-TiacciTrifonov2011_28-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP et al. (June 2011). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3689585">"BRAF mutations in hairy-cell leukemia"</a>. <i>N. Engl. J. Med.</i> <b>364</b> (24): 2305–15. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1056%2FNEJMoa1014209">10.1056/NEJMoa1014209</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3689585">3689585</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21663470">21663470</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=BRAF+mutations+in+hairy-cell+leukemia&amp;rft.au=Ambrosetti%2C+A&amp;rft.au=Arcaini%2C+L&amp;rft.au=Bigerna%2C+B&amp;rft.au=Capponi%2C+M&amp;rft.au=Di+Raimondo%2C+F&amp;rft.au=Elliott%2C+O&amp;rft.au=Falini%2C+B&amp;rft.au=Farinelli%2C+L&amp;rft.aufirst=E&amp;rft.au=Fo%C3%A0%2C+R&amp;rft.au=Forconi%2C+F&amp;rft.au=Haferlach%2C+C&amp;rft.au=Haferlach%2C+T&amp;rft.au=Holmes%2C+A&amp;rft.au=Inghirami%2C+G&amp;rft.au=Kern%2C+W&amp;rft.aulast=Tiacci&amp;rft.au=Liso%2C+A&amp;rft.au=Mannucci%2C+R&amp;rft.au=Martelli%2C+MP&amp;rft.au=Musto%2C+P&amp;rft.au=Pacini%2C+R&amp;rft.au=Pasqualucci%2C+L&amp;rft.au=Patti%2C+C&amp;rft.au=Pettirossi%2C+V&amp;rft.au=Pileri%2C+S&amp;rft.au=Pizzolo%2C+G&amp;rft.au=Pucciarini%2C+A&amp;rft.au=Pulsoni%2C+A&amp;rft.au=Rabadan%2C+R&amp;rft.au=Schiavoni%2C+G&amp;rft.au=Schnittger%2C+S&amp;rft.au=Semenzato%2C+G&amp;rft.au=Sportoletti%2C+P&amp;rft.au=Tiacci%2C+E&amp;rft.au=Trentin%2C+L&amp;rft.au=Trifonov%2C+V&amp;rft.au=Wells%2C+VA&amp;rft.date=June+2011&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3689585&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMoa1014209&amp;rft_id=info%3Apmc%2F3689585&amp;rft_id=info%3Apmid%2F21663470&amp;rft.issue=24&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.pages=2305-15&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=364" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-29"><span class="mw-cite-backlink"><b><a href="#cite_ref-29">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://scienceblog.cancerresearchuk.org/2011/06/11/research-on-hairy-cell-leukaemia-shows-the-promise-of-new-dna-scanning-technologies/">Research on hairy-cell leukaemia shows the promise of new DNA-scanning technologies</a> - Cancer Research UK science blog</span></li>
<li id="cite_note-30"><span class="mw-cite-backlink"><b><a href="#cite_ref-30">^</a></b></span> <span class="reference-text"><span class="citation journal">Vanhentenrijk V, De Wolf-Peeters C, Wlodarska I, Belgian Programme of Interuniversity Poles of Attraction (2004). <a rel="nofollow" class="external text" href="http://bloodjournal.hematologylibrary.org/cgi/content/abstract/bloodjournal;104/1/250">"Comparative expressed sequence hybridization studies of hairy cell leukemia show uniform expression profile and imprint of spleen signature"</a>. <i>Blood</i> <b>104</b> (1): 250–5. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1182%2Fblood-2004-01-0181">10.1182/blood-2004-01-0181</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15016649">15016649</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Comparative+expressed+sequence+hybridization+studies+of+hairy+cell+leukemia+show+uniform+expression+profile+and+imprint+of+spleen+signature&amp;rft.au=Belgian+Programme+of+Interuniversity+Poles+of+Attraction&amp;rft.au=De+Wolf-Peeters%2C+C&amp;rft.aufirst=V&amp;rft.aulast=Vanhentenrijk&amp;rft.au=Vanhentenrijk%2C+V&amp;rft.au=Wlodarska%2C+I&amp;rft.date=2004&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcgi%2Fcontent%2Fabstract%2Fbloodjournal%3B104%2F1%2F250&amp;rft_id=info%3Adoi%2F10.1182%2Fblood-2004-01-0181&amp;rft_id=info%3Apmid%2F15016649&amp;rft.issue=1&amp;rft.jtitle=Blood&amp;rft.pages=250-5&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=104" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid16497968-31"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid16497968_31-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Ravandi F, Jorgensen JL, O'Brien SM, Verstovsek S, Koller CA, Faderl S et al. (June 2006). "Eradication of minimal residual disease in hairy cell leukemia". <i>Blood</i> <b>107</b> (12): 4658–62. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1182%2Fblood-2005-11-4590">10.1182/blood-2005-11-4590</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16497968">16497968</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Eradication+of+minimal+residual+disease+in+hairy+cell+leukemia&amp;rft.au=Faderl%2C+S&amp;rft.au=Ferrajoli%2C+A&amp;rft.aufirst=F&amp;rft.au=Freireich%2C+EJ&amp;rft.au=Giles%2C+FJ&amp;rft.au=Huang%2C+X&amp;rft.au=Jones%2C+D&amp;rft.au=Jorgensen%2C+JL&amp;rft.au=Kantarjian%2C+HM&amp;rft.au=Keating%2C+MJ&amp;rft.au=Koller%2C+CA&amp;rft.aulast=Ravandi&amp;rft.au=O%27Brien%2C+SM&amp;rft.au=Odinga%2C+S&amp;rft.au=Ravandi%2C+F&amp;rft.au=Thomas%2C+DA&amp;rft.au=Verstovsek%2C+S&amp;rft.au=Wierda%2C+WG&amp;rft.date=June+2006&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1182%2Fblood-2005-11-4590&amp;rft_id=info%3Apmid%2F16497968&amp;rft.issue=12&amp;rft.jtitle=Blood&amp;rft.pages=4658-62&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=107" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-32"><span class="mw-cite-backlink"><b><a href="#cite_ref-32">^</a></b></span> <span class="reference-text"><span class="citation journal">Robak T, Jamroziak K, Gora-Tybor J, Blonski JZ, Kasznicki M, Dwilewicz-Trojaczek J et al. (2007). <a rel="nofollow" class="external text" href="http://bloodjournal.hematologylibrary.org/cgi/content/abstract/bloodjournal;109/9/3672">"Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial"</a>. <i>Blood</i> <b>109</b> (9): 3672–5. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1182%2Fblood-2006-08-042929">10.1182/blood-2006-08-042929</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17209059">17209059</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Cladribine+in+a+weekly+versus+daily+schedule+for+untreated+active+hairy+cell+leukemia%3A+final+report+from+the+Polish+Adult+Leukemia+Group+%28PALG%29+of+a+prospective%2C+randomized%2C+multicenter+trial&amp;rft.au=Blonski%2C+JZ&amp;rft.au=Calbecka%2C+M&amp;rft.au=Ceglarek%2C+B&amp;rft.au=Dmoszynska%2C+A&amp;rft.au=Dwilewicz-Trojaczek%2C+J&amp;rft.au=Dybowicz%2C+J&amp;rft.aufirst=T&amp;rft.au=Gawronski%2C+K&amp;rft.au=Gora-Tybor%2C+J&amp;rft.au=Hellmann%2C+A&amp;rft.au=Jamroziak%2C+K&amp;rft.au=Kasznicki%2C+M&amp;rft.au=Kloczko%2C+J&amp;rft.au=Konopka%2C+L&amp;rft.au=Kostyra%2C+A&amp;rft.aulast=Robak&amp;rft.au=Lewandowski%2C+K&amp;rft.au=Molendowicz-Portala%2C+L&amp;rft.au=Nowak%2C+W&amp;rft.au=Robak%2C+T&amp;rft.au=Seferynska%2C+I&amp;rft.au=Skotnicki%2C+AB&amp;rft.au=Sokolowski%2C+J&amp;rft.au=Stella-Holowiecka%2C+B&amp;rft.au=Sulek%2C+K&amp;rft.au=Warzocha%2C+K&amp;rft.au=Wiater%2C+E&amp;rft.au=Wojtaszko%2C+M&amp;rft.au=Zawilska%2C+K&amp;rft.au=Zdunczyk%2C+A&amp;rft.au=Zdziarska%2C+B&amp;rft.date=2007&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcgi%2Fcontent%2Fabstract%2Fbloodjournal%3B109%2F9%2F3672&amp;rft_id=info%3Adoi%2F10.1182%2Fblood-2006-08-042929&amp;rft_id=info%3Apmid%2F17209059&amp;rft.issue=9&amp;rft.jtitle=Blood&amp;rft.pages=3672-5&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=109" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid16245328-33"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid16245328_33-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Else M, Ruchlemer R, Osuji N, Del Giudice I, Matutes E, Woodman A et al. (2005). "Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years". <i>Cancer</i> <b>104</b> (11): 2442–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1002%2Fcncr.21447">10.1002/cncr.21447</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16245328">16245328</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Long+remissions+in+hairy+cell+leukemia+with+purine+analogs%3A+a+report+of+219+patients+with+a+median+follow-up+of+12.5+years&amp;rft.au=Catovsky%2C+D&amp;rft.au=Dearden%2C+C&amp;rft.au=Del+Giudice%2C+I&amp;rft.au=Else%2C+M&amp;rft.aufirst=M&amp;rft.aulast=Else&amp;rft.au=Matutes%2C+E&amp;rft.au=Osuji%2C+N&amp;rft.au=Ruchlemer%2C+R&amp;rft.au=Swansbury%2C+J&amp;rft.au=Woodman%2C+A&amp;rft.au=Wotherspoon%2C+A&amp;rft.date=2005&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2Fcncr.21447&amp;rft_id=info%3Apmid%2F16245328&amp;rft.issue=11&amp;rft.jtitle=Cancer&amp;rft.pages=2442-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=104" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-34"><span class="mw-cite-backlink"><b><a href="#cite_ref-34">^</a></b></span> <span class="reference-text"><span class="citation journal">Thomas DA, O'Brien S, Bueso-Ramos C, Faderl S, Keating MJ, Giles FJ et al. (2003). <a rel="nofollow" class="external text" href="http://bloodjournal.hematologylibrary.org/cgi/content/abstract/102/12/3906">"Rituximab in relapsed or refractory hairy cell leukemia"</a>. <i>Blood</i> <b>102</b> (12): 3906–11. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1182%2Fblood-2003-02-0630">10.1182/blood-2003-02-0630</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12816862">12816862</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Rituximab+in+relapsed+or+refractory+hairy+cell+leukemia&amp;rft.au=Bueso-Ramos%2C+C&amp;rft.au=Cortes%2C+J&amp;rft.au=Faderl%2C+S&amp;rft.aufirst=DA&amp;rft.au=Giles%2C+FJ&amp;rft.au=Kantarjian%2C+HM&amp;rft.au=Keating%2C+MJ&amp;rft.aulast=Thomas&amp;rft.au=O%27Brien%2C+S&amp;rft.au=Thomas%2C+DA&amp;rft.date=2003&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcgi%2Fcontent%2Fabstract%2F102%2F12%2F3906&amp;rft_id=info%3Adoi%2F10.1182%2Fblood-2003-02-0630&amp;rft_id=info%3Apmid%2F12816862&amp;rft.issue=12&amp;rft.jtitle=Blood&amp;rft.pages=3906-11&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=102" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-35"><span class="mw-cite-backlink"><b><a href="#cite_ref-35">^</a></b></span> <span class="reference-text"><span class="citation journal">Nieva J, Bethel K, Saven A (2003). <a rel="nofollow" class="external text" href="http://bloodjournal.hematologylibrary.org/cgi/content/full/102/3/810">"Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia"</a>. <i>Blood</i> <b>102</b> (3): 810–3. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1182%2Fblood-2003-01-0014">10.1182/blood-2003-01-0014</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12663446">12663446</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Phase+2+study+of+rituximab+in+the+treatment+of+cladribine-failed+patients+with+hairy+cell+leukemia&amp;rft.au=Bethel%2C+K&amp;rft.aufirst=J&amp;rft.aulast=Nieva&amp;rft.au=Nieva%2C+J&amp;rft.au=Saven%2C+A&amp;rft.date=2003&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcgi%2Fcontent%2Ffull%2F102%2F3%2F810&amp;rft_id=info%3Adoi%2F10.1182%2Fblood-2003-01-0014&amp;rft_id=info%3Apmid%2F12663446&amp;rft.issue=3&amp;rft.jtitle=Blood&amp;rft.pages=810-3&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=102" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-36"><span class="mw-cite-backlink"><b><a href="#cite_ref-36">^</a></b></span> <span class="reference-text"><span class="citation journal">Narat S, Gandla J, Dogan A, Mehta A (August 2005). "Successful treatment of hairy cell leukemia variant with rituximab". <i>Leuk. Lymphoma</i> <b>46</b> (8): 1229–32. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1080%2F10428190500083433">10.1080/10428190500083433</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16085567">16085567</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Successful+treatment+of+hairy+cell+leukemia+variant+with+rituximab&amp;rft.au=Dogan%2C+A&amp;rft.aufirst=S&amp;rft.au=Gandla%2C+J&amp;rft.aulast=Narat&amp;rft.au=Mehta%2C+A&amp;rft.au=Narat%2C+S&amp;rft.date=August+2005&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1080%2F10428190500083433&amp;rft_id=info%3Apmid%2F16085567&amp;rft.issue=8&amp;rft.jtitle=Leuk.+Lymphoma&amp;rft.pages=1229-32&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=46" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-37"><span class="mw-cite-backlink"><b><a href="#cite_ref-37">^</a></b></span> <span class="reference-text"><i><a rel="nofollow" class="external text" href="http://www.emedicine.com/med/topic937.htm#section~medication">Hairy Cell Leukemia~medication</a></i> at <a href="/wiki/EMedicine" title="EMedicine">eMedicine</a></span></li>
<li id="cite_note-38"><span class="mw-cite-backlink"><b><a href="#cite_ref-38">^</a></b></span> <span class="reference-text"><span class="citation journal">Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU (January 1984). "Alpha interferon for induction of remission in hairy-cell leukemia". <i>N. Engl. J. Med.</i> <b>310</b> (1): 15–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1056%2FNEJM198401053100104">10.1056/NEJM198401053100104</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/6689734">6689734</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Alpha+interferon+for+induction+of+remission+in+hairy-cell+leukemia&amp;rft.aufirst=JR&amp;rft.au=Gutterman%2C+JU&amp;rft.au=Hersh%2C+EM&amp;rft.aulast=Quesada&amp;rft.au=Manning%2C+JT&amp;rft.au=Quesada%2C+JR&amp;rft.au=Reuben%2C+J&amp;rft.date=January+1984&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1056%2FNEJM198401053100104&amp;rft_id=info%3Apmid%2F6689734&amp;rft.issue=1&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.pages=15-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=310" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid3971043-39"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid3971043_39-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid3971043_39-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Ratain MJ, Golomb HM, Vardiman JW, Vokes EE, Jacobs RH, Daly K (1985). "Treatment of hairy cell leukemia with recombinant alpha 2 interferon". <i>Blood</i> <b>65</b> (3): 644–8. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/3971043">3971043</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Treatment+of+hairy+cell+leukemia+with+recombinant+alpha+2+interferon&amp;rft.au=Daly%2C+K&amp;rft.aufirst=MJ&amp;rft.au=Golomb%2C+HM&amp;rft.au=Jacobs%2C+RH&amp;rft.aulast=Ratain&amp;rft.au=Ratain%2C+MJ&amp;rft.au=Vardiman%2C+JW&amp;rft.au=Vokes%2C+EE&amp;rft.date=1985&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F3971043&amp;rft.issue=3&amp;rft.jtitle=Blood&amp;rft.pages=644-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=65" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid12091360-40"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid12091360_40-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid12091360_40-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Baker PK, Pettitt AR, Slupsky JR, Chen HJ, Glenn MA, Zuzel M et al. (2002). "Response of hairy cells to IFN-alpha involves induction of apoptosis through autocrine TNF-alpha and protection by adhesion". <i>Blood</i> <b>100</b> (2): 647–53. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1182%2Fblood.V100.2.647">10.1182/blood.V100.2.647</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12091360">12091360</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Response+of+hairy+cells+to+IFN-alpha+involves+induction+of+apoptosis+through+autocrine+TNF-alpha+and+protection+by+adhesion&amp;rft.au=Baker%2C+PK&amp;rft.au=Cawley%2C+JC&amp;rft.au=Chen%2C+HJ&amp;rft.aufirst=PK&amp;rft.au=Glenn%2C+MA&amp;rft.aulast=Baker&amp;rft.au=Pettitt%2C+AR&amp;rft.au=Slupsky%2C+JR&amp;rft.au=Zuzel%2C+M&amp;rft.date=2002&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1182%2Fblood.V100.2.647&amp;rft_id=info%3Apmid%2F12091360&amp;rft.issue=2&amp;rft.jtitle=Blood&amp;rft.pages=647-53&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=100" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-41"><span class="mw-cite-backlink"><b><a href="#cite_ref-41">^</a></b></span> <span class="reference-text"><span class="citation journal">Saven A, Burian C, Adusumalli J, Koziol JA (1999). <a rel="nofollow" class="external text" href="http://bloodjournal.hematologylibrary.org/cgi/content/full/93/8/2471">"Filgrastim for Cladribine-Induced Neutropenic Fever in Patients With Hairy Cell Leukemia"</a>. <i>Blood</i> <b>93</b> (8): 2471–7. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10194424">10194424</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Filgrastim+for+Cladribine-Induced+Neutropenic+Fever+in+Patients+With+Hairy+Cell+Leukemia&amp;rft.au=Adusumalli%2C+J&amp;rft.au=Burian%2C+C&amp;rft.aufirst=A&amp;rft.au=Koziol%2C+JA&amp;rft.aulast=Saven&amp;rft.au=Saven%2C+A&amp;rft.date=1999&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcgi%2Fcontent%2Ffull%2F93%2F8%2F2471&amp;rft_id=info%3Apmid%2F10194424&amp;rft.issue=8&amp;rft.jtitle=Blood&amp;rft.pages=2471-7&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=93" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-42"><span class="mw-cite-backlink"><b><a href="#cite_ref-42">^</a></b></span> <span class="reference-text"><span class="citation journal">Else M, Ruchlemer R, Osuji N, Del Giudice I, Matutes E, Woodman A et al. (December 2005). "Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years". <i>Cancer</i> <b>104</b> (11): 2442–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1002%2Fcncr.21447">10.1002/cncr.21447</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16245328">16245328</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Long+remissions+in+hairy+cell+leukemia+with+purine+analogs%3A+a+report+of+219+patients+with+a+median+follow-up+of+12.5+years&amp;rft.au=Catovsky%2C+D&amp;rft.au=Dearden%2C+C&amp;rft.au=Del+Giudice%2C+I&amp;rft.au=Else%2C+M&amp;rft.aufirst=M&amp;rft.aulast=Else&amp;rft.au=Matutes%2C+E&amp;rft.au=Osuji%2C+N&amp;rft.au=Ruchlemer%2C+R&amp;rft.au=Swansbury%2C+J&amp;rft.au=Woodman%2C+A&amp;rft.au=Wotherspoon%2C+A&amp;rft.date=December+2005&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2Fcncr.21447&amp;rft_id=info%3Apmid%2F16245328&amp;rft.issue=11&amp;rft.jtitle=Cancer&amp;rft.pages=2442-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=104" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-43"><span class="mw-cite-backlink"><b><a href="#cite_ref-43">^</a></b></span> <span class="reference-text"><span class="citation journal">Forconi F, Sozzi E, Cencini E, Zaja F, Intermesoli T, Stelitano C et al. (November 2009). <a rel="nofollow" class="external text" href="http://bloodjournal.hematologylibrary.org/cgi/content/full/114/21/4696">"Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single agent cladribine and with more aggressive behavior"</a>. <i>Blood</i> <b>114</b> (21): 4696–4702. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1182%2Fblood-2009-03-212449">10.1182/blood-2009-03-212449</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19667403">19667403</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Hairy+cell+leukemias+with+unmutated+IGHV+genes+define+the+minor+subset+refractory+to+single+agent+cladribine+and+with+more+aggressive+behavior&amp;rft.au=Baraldi%2C+A&amp;rft.au=Bertoni%2C+F&amp;rft.au=Cantaffa%2C+R&amp;rft.au=Cencini%2C+E&amp;rft.aufirst=F&amp;rft.au=Forconi%2C+F&amp;rft.au=Gallamini%2C+A&amp;rft.au=Gherlinzoni%2C+F&amp;rft.au=Gobbi%2C+M&amp;rft.au=Intermesoli%2C+T&amp;rft.aulast=Forconi&amp;rft.au=Lauria%2C+F&amp;rft.au=Leoncini%2C+L&amp;rft.au=Pileri%2C+SA&amp;rft.au=Pulsoni%2C+A&amp;rft.au=Raspadori%2C+D&amp;rft.au=Rigacci%2C+L&amp;rft.au=Rinaldi%2C+A&amp;rft.au=Sabattini%2C+E&amp;rft.au=Sozzi%2C+E&amp;rft.au=Stelitano%2C+C&amp;rft.au=Tassi%2C+M&amp;rft.au=Zaccaria%2C+A&amp;rft.au=Zaja%2C+F&amp;rft.date=November+2009&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fbloodjournal.hematologylibrary.org%2Fcgi%2Fcontent%2Ffull%2F114%2F21%2F4696&amp;rft_id=info%3Adoi%2F10.1182%2Fblood-2009-03-212449&amp;rft_id=info%3Apmid%2F19667403&amp;rft.issue=21&amp;rft.jtitle=Blood&amp;rft.pages=4696-4702&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=114" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-44"><span class="mw-cite-backlink"><b><a href="#cite_ref-44">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external free" href="http://www.euclidmanagers.com/downloads/legrev/rblegrev/RTBaugust.pdf">http://www.euclidmanagers.com/downloads/legrev/rblegrev/RTBaugust.pdf</a></span></li>
<li id="cite_note-45"><span class="mw-cite-backlink"><b><a href="#cite_ref-45">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external free" href="http://www.cambridgeantibody.com/home/glossary">http://www.cambridgeantibody.com/home/glossary</a></span></li>
<li id="cite_note-46"><span class="mw-cite-backlink"><b><a href="#cite_ref-46">^</a></b></span> <span class="reference-text"><span class="citation journal">Au WY, Klasa RJ, Gallagher R, Le N, Gascoyne RD, Connors JM (August 1998). <a rel="nofollow" class="external text" href="http://www.bloodjournal.org/cgi/pmidlookup?view=long&amp;pmid=9694703">"Second malignancies in patients with hairy cell leukemia in british columbia: a 20-year experience"</a>. <i>Blood</i> <b>92</b> (4): 1160–4. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/9694703">9694703</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Second+malignancies+in+patients+with+hairy+cell+leukemia+in+british+columbia%3A+a+20-year+experience&amp;rft.au=Au%2C+WY&amp;rft.au=Connors%2C+JM&amp;rft.aufirst=WY&amp;rft.au=Gallagher%2C+R&amp;rft.au=Gascoyne%2C+RD&amp;rft.au=Klasa%2C+RJ&amp;rft.aulast=Au&amp;rft.au=Le%2C+N&amp;rft.date=August+1998&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.bloodjournal.org%2Fcgi%2Fpmidlookup%3Fview%3Dlong%26pmid%3D9694703&amp;rft_id=info%3Apmid%2F9694703&amp;rft.issue=4&amp;rft.jtitle=Blood&amp;rft.pages=1160-4&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=92" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-47"><span class="mw-cite-backlink"><b><a href="#cite_ref-47">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.pennhealth.com/ency/article/000592.htm">"Hairy cell leukemia"</a><span class="reference-accessdate">. Retrieved <span class="nowrap">2007-09-07</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.btitle=Hairy+cell+leukemia&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.pennhealth.com%2Fency%2Farticle%2F000592.htm&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid11554237-48"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid11554237_48-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Yetgin S, Olcay L, Yenicesu I, Oner AF, Cağlar M (September 2001). "Relapse in hairy cell leukemia due to isolated nodular skin infiltration". <i>Pediatr Hematol Oncol</i> <b>18</b> (6): 415–7. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1080%2F088800101316922047">10.1080/088800101316922047</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11554237">11554237</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Relapse+in+hairy+cell+leukemia+due+to+isolated+nodular+skin+infiltration&amp;rft.au=Ca%C4%9Flar%2C+M&amp;rft.aufirst=S&amp;rft.aulast=Yetgin&amp;rft.au=Olcay%2C+L&amp;rft.au=Oner%2C+AF&amp;rft.au=Yenicesu%2C+I&amp;rft.au=Yetgin%2C+S&amp;rft.date=September+2001&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1080%2F088800101316922047&amp;rft_id=info%3Apmid%2F11554237&amp;rft.issue=6&amp;rft.jtitle=Pediatr+Hematol+Oncol&amp;rft.pages=415-7&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=18" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-49"><span class="mw-cite-backlink"><b><a href="#cite_ref-49">^</a></b></span> <span class="reference-text"><span class="citation journal">Gramatovici M, Bennett JM, Hiscock JG, Grewal KS (April 1993). "Three cases of familial hairy cell leukemia". <i>Am. J. Hematol.</i> <b>42</b> (4): 337–9. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1002%2Fajh.2830420402">10.1002/ajh.2830420402</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/8493982">8493982</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Three+cases+of+familial+hairy+cell+leukemia&amp;rft.au=Bennett%2C+JM&amp;rft.aufirst=M&amp;rft.au=Gramatovici%2C+M&amp;rft.au=Grewal%2C+KS&amp;rft.au=Hiscock%2C+JG&amp;rft.aulast=Gramatovici&amp;rft.date=April+1993&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2Fajh.2830420402&amp;rft_id=info%3Apmid%2F8493982&amp;rft.issue=4&amp;rft.jtitle=Am.+J.+Hematol.&amp;rft.pages=337-9&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=42" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid19276454-50"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid19276454_50-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Holzman D (March 2009). "Has success spoiled hairy cell leukemia research? Key questions go unanswered, despite big gains". <i>J. Natl. Cancer Inst.</i> <b>101</b> (6): 370–3. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1093%2Fjnci%2Fdjp051">10.1093/jnci/djp051</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19276454">19276454</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.atitle=Has+success+spoiled+hairy+cell+leukemia+research%3F+Key+questions+go+unanswered%2C+despite+big+gains&amp;rft.aufirst=D&amp;rft.au=Holzman%2C+D&amp;rft.aulast=Holzman&amp;rft.date=March+2009&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1093%2Fjnci%2Fdjp051&amp;rft_id=info%3Apmid%2F19276454&amp;rft.issue=6&amp;rft.jtitle=J.+Natl.+Cancer+Inst.&amp;rft.pages=370-3&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=101" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-51"><span class="mw-cite-backlink"><b><a href="#cite_ref-51">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external free" href="http://www.hairycellleukemia.org/">http://www.hairycellleukemia.org/</a></span></li>
<li id="cite_note-52"><span class="mw-cite-backlink"><b><a href="#cite_ref-52">^</a></b></span> <span class="reference-text">Clinical trial number <i><a rel="nofollow" class="external text" href="http://www.clinicaltrials.gov/show/NCT00074048">NCT00074048</a></i> at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></span></li>
<li id="cite_note-53"><span class="mw-cite-backlink"><b><a href="#cite_ref-53">^</a></b></span> <span class="reference-text">Clinical trial number <i><a rel="nofollow" class="external text" href="http://www.clinicaltrials.gov/show/NCT00462189">NCT00462189</a></i> at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></span></li>
<li id="cite_note-54"><span class="mw-cite-backlink"><b><a href="#cite_ref-54">^</a></b></span> <span class="reference-text">Clinical trial number <i><a rel="nofollow" class="external text" href="http://www.clinicaltrials.gov/show/NCT00337311">NCT00337311</a></i> at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></span></li>
<li id="cite_note-55"><span class="mw-cite-backlink"><b><a href="#cite_ref-55">^</a></b></span> <span class="reference-text">For example, trial <a rel="nofollow" class="external text" href="http://clinicaltrials.gov/show/NCT00412594">NCT00412594</a> and <a rel="nofollow" class="external text" href="http://clinicaltrials.gov/show/NCT00923013">NCT00923013</a></span></li>
<li id="cite_note-56"><span class="mw-cite-backlink"><b><a href="#cite_ref-56">^</a></b></span> <span class="reference-text"><span class="citation web">Cawley, John. <a rel="nofollow" class="external text" href="http://www.hairycell.org/content/researchers/unanswered-questions/biology-disease-including-unanswered-questions">"The Biology of the Disease Including Unanswered Questions | HairyCell.org"</a><span class="reference-accessdate">. Retrieved <span class="nowrap">2010-06-23</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AHairy+cell+leukemia&amp;rft.au=Cawley%2C+John&amp;rft.aulast=Cawley%2C+John&amp;rft.btitle=The+Biology+of+the+Disease+Including+Unanswered+Questions+%26%23124%3B+HairyCell.org&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.hairycell.org%2Fcontent%2Fresearchers%2Funanswered-questions%2Fbiology-disease-including-unanswered-questions&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
</ol>
</div>
<h2><span class="mw-headline" id="External_links">External links</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Hairy_cell_leukemia&amp;action=edit&amp;section=21" title="Edit section: External links">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul>
<li><a rel="nofollow" class="external text" href="http://www.cancer.gov/cancertopics/pdq/treatment/hairy-cell-leukemia">About HCL</a> at the US <a href="/wiki/National_Cancer_Institute" title="National Cancer Institute">National Cancer Institute</a></li>
<li><a rel="nofollow" class="external text" href="http://cancer.osu.edu/viewer/Pages/index.aspx?p=514">History of HCL and the Godmother of HCL</a></li>
</ul>
<table class="navbox" style="border-spacing:0">
<tr>
<td style="padding:2px">
<table class="nowraplinks collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Lymphoid_malignancy" title="Template:Lymphoid malignancy"><span title="View this template" style=";;background:none transparent;border:none;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Lymphoid_malignancy" title="Template talk:Lymphoid malignancy"><span title="Discuss this template" style=";;background:none transparent;border:none;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Lymphoid_malignancy&amp;action=edit"><span title="Edit this template" style=";;background:none transparent;border:none;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%"><a href="/wiki/Tumors_of_the_hematopoietic_and_lymphoid_tissues" title="Tumors of the hematopoietic and lymphoid tissues">Hematological malignancy</a>/<a href="/wiki/Leukemia" title="Leukemia">leukemia</a> histology (<a href="/wiki/International_Classification_of_Diseases_for_Oncology#.289590.E2.80.939999.29_Hematologic_.28Leukemias.2C_Lymphomas_and_related_disorders.29" title="International Classification of Diseases for Oncology">ICD-O 9590–9989</a>, <a href="/wiki/ICD-10_Chapter_II:_Neoplasms#.28C81.E2.80.93C96.29_Malignant_neoplasms.2C_stated_or_presumed_to_be_primary.2C_of_lymphoid.2C_haematopoietic_and_related_tissue" title="ICD-10 Chapter II: Neoplasms">C81–C96</a>, <a href="/wiki/List_of_ICD-9_codes_140%E2%80%93239:_neoplasms#Malignant_neoplasm_of_lymphatic_and_hematopoietic_tissue_.28200.E2.80.93208.29" title="List of ICD-9 codes 140–239: neoplasms">200–208</a>)<br />
<a href="/wiki/Lymphocyte" title="Lymphocyte">Lymphoid</a>/<a href="/wiki/Lymphoproliferative_disorders" title="Lymphoproliferative disorders">Lymphoproliferative</a>, <a href="/wiki/Lymphoma" title="Lymphoma">Lymphomas</a>/<a href="/wiki/Lymphoid_leukemia" title="Lymphoid leukemia">Lymphoid leukemias</a> (9590–9739, 9800–9839)</div>
</th>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<td colspan="2" class="navbox-list navbox-odd hlist" style="width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Lymphoma#Mature_B_cell_neoplasms" title="Lymphoma">B cell</a><br />
(<a href="/wiki/B-cell_lymphoma" title="B-cell lymphoma">lymphoma</a>,<br />
<a href="/wiki/B-cell_leukemia" title="B-cell leukemia">leukemia</a>)<br />
(most <a href="/wiki/CD19" title="CD19">CD19</a>
<ul>
<li><a href="/wiki/CD20" title="CD20">CD20</a>)</li>
</ul>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group">By development/<br />
marker</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Terminal_deoxynucleotidyl_transferase" title="Terminal deoxynucleotidyl transferase">TdT+</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Acute_lymphoblastic_leukemia" title="Acute lymphoblastic leukemia">ALL</a> (<a href="/wiki/Precursor_B-cell_lymphoblastic_leukemia" title="Precursor B-cell lymphoblastic leukemia">Precursor B acute lymphoblastic leukemia/lymphoma</a>)</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/CD5_(protein)" title="CD5 (protein)">CD5</a>+</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><i><a href="/wiki/Naive_B_cell" title="Naive B cell">naive B cell</a></i> (<a href="/wiki/B-cell_chronic_lymphocytic_leukemia" title="B-cell chronic lymphocytic leukemia">CLL/SLL</a>)</li>
</ul>
<ul>
<li><i><a href="/wiki/Mantle_zone" title="Mantle zone">mantle zone</a></i> (<a href="/wiki/Mantle_cell_lymphoma" title="Mantle cell lymphoma">Mantle cell</a>)</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/CD22" title="CD22">CD22</a>+</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/B-cell_prolymphocytic_leukemia" title="B-cell prolymphocytic leukemia">Prolymphocytic</a></li>
<li><i><a href="/wiki/CD11c" title="CD11c">CD11c+</a></i> (<strong class="selflink">Hairy cell leukemia</strong>)</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/CD79A" title="CD79A">CD79a</a>+</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><i><a href="/wiki/Germinal_center" title="Germinal center">germinal center</a>/<a href="/wiki/Follicular_B_cell" title="Follicular B cell">follicular B cell</a></i> (<a href="/wiki/Follicular_lymphoma" title="Follicular lymphoma">Follicular</a></li>
<li><a href="/wiki/Burkitt%27s_lymphoma" title="Burkitt's lymphoma">Burkitt's</a></li>
<li><a href="/wiki/GCB_DLBCL" title="GCB DLBCL" class="mw-redirect">GCB DLBCL</a></li>
<li><a href="/wiki/Primary_cutaneous_follicular_lymphoma" title="Primary cutaneous follicular lymphoma" class="mw-redirect">Primary cutaneous follicular lymphoma</a>)</li>
</ul>
<ul>
<li><i><a href="/wiki/Marginal_zone_B-cell_lymphoma" title="Marginal zone B-cell lymphoma">marginal zone</a>/<a href="/wiki/Marginal-zone_B_cell" title="Marginal-zone B cell" class="mw-redirect">marginal-zone B cell</a></i> (<a href="/wiki/Splenic_marginal_zone_lymphoma" title="Splenic marginal zone lymphoma">Splenic marginal zone</a></li>
<li><a href="/wiki/MALT_lymphoma" title="MALT lymphoma">MALT</a></li>
<li><a href="/wiki/Nodal_marginal_zone_B_cell_lymphoma" title="Nodal marginal zone B cell lymphoma">Nodal marginal zone</a></li>
<li><a href="/wiki/Primary_cutaneous_marginal_zone_lymphoma" title="Primary cutaneous marginal zone lymphoma">Primary cutaneous marginal zone lymphoma</a>)</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Reed-Sternberg_cell" title="Reed-Sternberg cell" class="mw-redirect">RS</a> (<a href="/wiki/CD15" title="CD15">CD15</a>+, <a href="/wiki/CD30" title="CD30">CD30</a>+)</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Hodgkin%27s_lymphoma" title="Hodgkin's lymphoma">Classic Hodgkin's lymphoma</a> (<a href="/wiki/Nodular_sclerosis" title="Nodular sclerosis">Nodular sclerosis</a>)</li>
<li><i><a href="/wiki/CD20" title="CD20">CD20+</a></i> (<a href="/wiki/Nodular_lymphocyte_predominant_Hodgkin%27s_lymphoma" title="Nodular lymphocyte predominant Hodgkin's lymphoma">Nodular lymphocyte predominant Hodgkin's lymphoma</a>)</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Plasma_cell_dyscrasia" title="Plasma cell dyscrasia">PCDs</a>/<a href="/wiki/Paraproteinemia" title="Paraproteinemia">PP</a><br />
(<a href="/wiki/CD38" title="CD38">CD38</a>+/<a href="/wiki/CD138" title="CD138" class="mw-redirect">CD138</a>+)</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><i>see <a href="/wiki/Template:Immunoproliferative_immunoglobulin_disorders" title="Template:Immunoproliferative immunoglobulin disorders">immunoproliferative immunoglobulin disorders</a></i></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">By infection</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><i><a href="/wiki/Kaposi%27s_sarcoma-associated_herpesvirus" title="Kaposi's sarcoma-associated herpesvirus">KSHV</a></i> (<a href="/wiki/Primary_effusion_lymphoma" title="Primary effusion lymphoma">Primary effusion</a>)</li>
<li><i><a href="/wiki/Epstein-Barr_virus" title="Epstein-Barr virus" class="mw-redirect">EBV</a></i> (<a href="/wiki/Lymphomatoid_granulomatosis" title="Lymphomatoid granulomatosis">Lymphomatoid granulomatosis</a></li>
<li><a href="/wiki/Post-transplant_lymphoproliferative_disorder" title="Post-transplant lymphoproliferative disorder">Post-transplant lymphoproliferative disorder</a>)</li>
<li><i><a href="/wiki/HIV" title="HIV">HIV</a></i> (<a href="/wiki/AIDS-related_lymphoma" title="AIDS-related lymphoma">AIDS-related lymphoma</a>)</li>
<li><i><a href="/wiki/Helicobacter_pylori" title="Helicobacter pylori">Helicobacter pylori</a></i> (<a href="/wiki/MALT_lymphoma" title="MALT lymphoma">MALT lymphoma</a>)</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Cutaneous_B-cell_lymphoma" title="Cutaneous B-cell lymphoma">Cutaneous</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Diffuse_large_B-cell_lymphoma" title="Diffuse large B-cell lymphoma">Diffuse large B-cell lymphoma</a></li>
<li><a href="/wiki/Intravascular_large_B-cell_lymphoma" title="Intravascular large B-cell lymphoma">Intravascular large B-cell lymphoma</a></li>
<li><a href="/wiki/Primary_cutaneous_marginal_zone_lymphoma" title="Primary cutaneous marginal zone lymphoma">Primary cutaneous marginal zone lymphoma</a></li>
<li><a href="/wiki/Primary_cutaneous_immunocytoma" title="Primary cutaneous immunocytoma">Primary cutaneous immunocytoma</a></li>
<li><a href="/wiki/Plasmacytoma" title="Plasmacytoma">Plasmacytoma</a></li>
<li><a href="/wiki/Plasmacytosis" title="Plasmacytosis">Plasmacytosis</a></li>
<li><a href="/wiki/Primary_cutaneous_follicular_lymphoma" title="Primary cutaneous follicular lymphoma" class="mw-redirect">Primary cutaneous follicular lymphoma</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Lymphoma#Mature_T_cell_and_natural_killer_.28NK.29_cell_neoplasms" title="Lymphoma">T/NK</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/T_cell" title="T cell">T cell</a><br />
(<a href="/wiki/T-cell_lymphoma" title="T-cell lymphoma">lymphoma</a>,<br />
<a href="/wiki/T-cell_leukemia" title="T-cell leukemia">leukemia</a>)<br />
(most <a href="/wiki/CD3_(immunology)" title="CD3 (immunology)">CD3</a>
<ul>
<li><a href="/wiki/CD4" title="CD4">CD4</a></li>
<li><a href="/wiki/CD8" title="CD8">CD8</a>)</li>
</ul>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group">By development/<br />
marker</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Terminal_deoxynucleotidyl_transferase" title="Terminal deoxynucleotidyl transferase">TdT+</a>: <a href="/wiki/Acute_lymphoblastic_leukemia" title="Acute lymphoblastic leukemia">ALL</a> (<a href="/wiki/Precursor_T-cell_lymphoblastic_leukemia" title="Precursor T-cell lymphoblastic leukemia" class="mw-redirect">Precursor T acute lymphoblastic leukemia/lymphoma</a>)</li>
</ul>
<ul>
<li><i><a href="/wiki/Prolymphocyte" title="Prolymphocyte">prolymphocyte</a></i> (<a href="/wiki/T-cell_prolymphocytic_leukemia" title="T-cell prolymphocytic leukemia">Prolymphocytic</a>)</li>
</ul>
<ul>
<li><i><a href="/wiki/CD30" title="CD30">CD30+</a></i> (<a href="/wiki/Anaplastic_large-cell_lymphoma" title="Anaplastic large-cell lymphoma">Anaplastic large-cell lymphoma</a></li>
<li><a href="/wiki/Lymphomatoid_papulosis" title="Lymphomatoid papulosis">Lymphomatoid papulosis type A</a>)</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Cutaneous_T-cell_lymphoma" title="Cutaneous T-cell lymphoma" class="mw-redirect">Cutaneous</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Mycosis_fungoides" title="Mycosis fungoides">MF+variants</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><i>indolent:</i> <a href="/wiki/Mycosis_fungoides" title="Mycosis fungoides">Mycosis fungoides</a></li>
<li><a href="/wiki/Pagetoid_reticulosis" title="Pagetoid reticulosis">Pagetoid reticulosis</a></li>
<li><a href="/wiki/Granulomatous_slack_skin" title="Granulomatous slack skin">Granulomatous slack skin</a></li>
</ul>
<p><i>aggressive:</i> <a href="/wiki/S%C3%A9zary_disease" title="Sézary disease">Sézary disease</a></p>
<ul>
<li><a href="/wiki/Adult_T-cell_leukemia/lymphoma" title="Adult T-cell leukemia/lymphoma">Adult T-cell leukemia/lymphoma</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Non-MF</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/CD30" title="CD30">CD30</a>-: <a href="/wiki/Non-mycosis_fungoides_CD30%E2%88%92_cutaneous_large_T-cell_lymphoma" title="Non-mycosis fungoides CD30− cutaneous large T-cell lymphoma">Non-mycosis fungoides CD30− cutaneous large T-cell lymphoma</a></li>
<li><a href="/wiki/Pleomorphic_T-cell_lymphoma" title="Pleomorphic T-cell lymphoma">Pleomorphic T-cell lymphoma</a></li>
<li><a href="/wiki/Lymphomatoid_papulosis" title="Lymphomatoid papulosis">Lymphomatoid papulosis type B</a></li>
</ul>
<ul>
<li><a href="/wiki/CD30" title="CD30">CD30</a>+: <a href="/wiki/CD30%2B_cutaneous_T-cell_lymphoma" title="CD30+ cutaneous T-cell lymphoma">CD30+ cutaneous T-cell lymphoma</a></li>
<li><a href="/wiki/Secondary_cutaneous_CD30%2B_large_cell_lymphoma" title="Secondary cutaneous CD30+ large cell lymphoma" class="mw-redirect">Secondary cutaneous CD30+ large cell lymphoma</a></li>
<li><a href="/wiki/Lymphomatoid_papulosis" title="Lymphomatoid papulosis">Lymphomatoid papulosis type A</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Other <a href="/wiki/Peripheral_T-cell_lymphoma" title="Peripheral T-cell lymphoma">peripheral</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Hepatosplenic_T-cell_lymphoma" title="Hepatosplenic T-cell lymphoma">Hepatosplenic</a></li>
<li><a href="/wiki/Angioimmunoblastic_T-cell_lymphoma" title="Angioimmunoblastic T-cell lymphoma">Angioimmunoblastic</a></li>
<li><a href="/wiki/Enteropathy-associated_T-cell_lymphoma" title="Enteropathy-associated T-cell lymphoma">Enteropathy-associated T-cell lymphoma</a></li>
<li><a href="/wiki/Peripheral_T-cell_lymphoma-Not-Otherwise-Specified" title="Peripheral T-cell lymphoma-Not-Otherwise-Specified" class="mw-redirect">Peripheral T-cell lymphoma-Not-Otherwise-Specified</a> (<a href="/wiki/Lennert_lymphoma" title="Lennert lymphoma">Lennert lymphoma</a>)</li>
<li><a href="/wiki/Subcutaneous_T-cell_lymphoma" title="Subcutaneous T-cell lymphoma">Subcutaneous T-cell lymphoma</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">By infection</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><i><a href="/wiki/Human_T-lymphotropic_virus_1" title="Human T-lymphotropic virus 1">HTLV-1</a></i> (<a href="/wiki/Adult_T-cell_leukemia/lymphoma" title="Adult T-cell leukemia/lymphoma">Adult T-cell leukemia/lymphoma</a>)</li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Lymphoma#Mature_T_cell_and_natural_killer_.28NK.29_cell_neoplasms" title="Lymphoma">NK cell</a>/<br />
(most <a href="/wiki/CD56" title="CD56" class="mw-redirect">CD56</a>)</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Aggressive_NK-cell_leukemia" title="Aggressive NK-cell leukemia">Aggressive NK-cell leukemia</a></li>
<li><a href="/wiki/Blastic_NK_cell_lymphoma" title="Blastic NK cell lymphoma">Blastic NK cell lymphoma</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">T or NK</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><i><a href="/wiki/Epstein-Barr_virus" title="Epstein-Barr virus" class="mw-redirect">EBV</a></i> (<a href="/wiki/Extranodal_NK-T-cell_lymphoma" title="Extranodal NK-T-cell lymphoma" class="mw-redirect">Extranodal NK-T-cell lymphoma</a>/<a href="/wiki/Angiocentric_lymphoma" title="Angiocentric lymphoma" class="mw-redirect">Angiocentric lymphoma</a>)</li>
<li><a href="/wiki/Large_granular_lymphocytic_leukemia" title="Large granular lymphocytic leukemia">Large granular lymphocytic leukemia</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Lymphoid+myeloid</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Acute_biphenotypic_leukaemia" title="Acute biphenotypic leukaemia">Acute biphenotypic leukaemia</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Lymphocytosis" title="Lymphocytosis">Lymphocytosis</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Lymphoproliferative_disorders" title="Lymphoproliferative disorders">Lymphoproliferative disorders</a> (<a href="/wiki/X-linked_lymphoproliferative_disease" title="X-linked lymphoproliferative disease">X-linked lymphoproliferative disease</a></li>
<li><a href="/wiki/Autoimmune_lymphoproliferative_syndrome" title="Autoimmune lymphoproliferative syndrome">Autoimmune lymphoproliferative syndrome</a>)</li>
<li><a href="/wiki/Leukemoid_reaction" title="Leukemoid reaction">Leukemoid reaction</a></li>
<li><a href="/wiki/Diffuse_infiltrative_lymphocytosis_syndrome" title="Diffuse infiltrative lymphocytosis syndrome">Diffuse infiltrative lymphocytosis syndrome</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Cutaneous_lymphoid_hyperplasia" title="Cutaneous lymphoid hyperplasia">Cutaneous lymphoid hyperplasia</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Cutaneous_lymphoid_hyperplasia" title="Cutaneous lymphoid hyperplasia">Cutaneous lymphoid hyperplasia</a>
<ul>
<li><a href="/wiki/Cutaneous_lymphoid_hyperplasia_with_bandlike_and_perivascular_patterns" title="Cutaneous lymphoid hyperplasia with bandlike and perivascular patterns" class="mw-redirect">with bandlike and perivascular patterns</a></li>
<li><a href="/wiki/Cutaneous_lymphoid_hyperplasia_with_nodular_pattern" title="Cutaneous lymphoid hyperplasia with nodular pattern" class="mw-redirect">with nodular pattern</a></li>
</ul>
</li>
<li><a href="/wiki/Jessner_lymphocytic_infiltrate_of_the_skin" title="Jessner lymphocytic infiltrate of the skin" class="mw-redirect">Jessner lymphocytic infiltrate of the skin</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;">
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Lymph_immune_and_complement_navs" title="Template:Lymph immune and complement navs"><span title="View this template" style=";;background:none transparent;border:none;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Lymph_immune_and_complement_navs" title="Template talk:Lymph immune and complement navs"><span title="Discuss this template" style=";;background:none transparent;border:none;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Lymph_immune_and_complement_navs&amp;action=edit"><span title="Edit this template" style=";;background:none transparent;border:none;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%">Index of the <a href="/wiki/Immune_system" title="Immune system">immune system</a></div>
</th>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Description</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Template:Lymphocytic_immune_system" title="Template:Lymphocytic immune system">Physiology</a>
<ul>
<li><a href="/wiki/Template:Lymphocytes" title="Template:Lymphocytes">cells</a></li>
<li><a href="/wiki/Template:Autoantigens" title="Template:Autoantigens">autoantigens</a></li>
<li><a href="/wiki/Template:Autoantibodies" title="Template:Autoantibodies">autoantibodies</a></li>
<li><a href="/wiki/Template:Complement_system" title="Template:Complement system">complement</a></li>
<li><a href="/wiki/Template:Surface_antigens" title="Template:Surface antigens">surface antigens</a></li>
<li><a href="/wiki/Template:Immunoglobulin_superfamily_immune_receptors" title="Template:Immunoglobulin superfamily immune receptors">IG receptors</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Disease</th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Template:Allergic_conditions" title="Template:Allergic conditions">Allergies</a></li>
<li><a href="/wiki/Template:Lymphoid_and_complement_immunodeficiency" title="Template:Lymphoid and complement immunodeficiency">Immunodeficiency</a></li>
<li><a href="/wiki/Template:Immunoproliferative_immunoglobulin_disorders" title="Template:Immunoproliferative immunoglobulin disorders">Immunoproliferative immunoglobulin disorders</a></li>
<li><a href="/wiki/Template:Hypersensitivity_and_autoimmune_diseases" title="Template:Hypersensitivity and autoimmune diseases">Hypersensitivity and autoimmune disorders</a></li>
<li><a href="/wiki/Template:Lymphoid_malignancy" title="Template:Lymphoid malignancy">Neoplasms and cancer</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Treatment</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Template:Immunologic_techniques_and_tests" title="Template:Immunologic techniques and tests">Procedures</a></li>
<li>Drugs
<ul>
<li><a href="/wiki/Template:Antihistamines" title="Template:Antihistamines">antihistamines</a></li>
<li><a href="/wiki/Template:Immunostimulants" title="Template:Immunostimulants">immunostimulants</a></li>
<li><a href="/wiki/Template:Immunosuppressants" title="Template:Immunosuppressants">immunosuppressants</a></li>
<li><a href="/wiki/Template:Monoclonals_for_immune_system" title="Template:Monoclonals for immune system">monoclonal antibodies</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
</table>


<!-- 
NewPP limit report
Parsed by mw1236
CPU time usage: 0.602 seconds
Real time usage: 0.669 seconds
Preprocessor visited node count: 5665/1000000
Preprocessor generated node count: 0/1500000
Post‐expand include size: 262418/2097152 bytes
Template argument size: 644/2097152 bytes
Highest expansion depth: 11/40
Expensive parser function count: 0/500
Lua time usage: 0.290/10.000 seconds
Lua memory usage: 3.07 MB/50 MB
-->

<!-- 
Transclusion expansion time report (%,ms,calls,template)
100.00%  542.684      1 - -total
 66.37%  360.168      1 - Template:Reflist
 45.40%  246.405     39 - Template:Vcite2_journal
 18.96%  102.878      8 - Template:Navbox
 13.62%   73.922      1 - Template:Infobox_disease
 11.92%   64.705      1 - Template:Infobox
  9.80%   53.210      1 - Template:Lymphoid_malignancy
  3.57%   19.380      1 - Template:Lymph_cell_navs
  2.64%   14.325      1 - Template:Comma_separated_entries
  2.31%   12.511      4 - Template:Cite_web
-->

<!-- Saved in parser cache with key enwiki:pcache:idhash:1094648-0!*!0!!en!4!* and timestamp 20150711033907 and revision id 665127407
 -->
<noscript><img src="//en.wikipedia.org/wiki/Special:CentralAutoLogin/start?type=1x1" alt="" title="" width="1" height="1" style="border: none; position: absolute;" /></noscript></div>					<div class="printfooter">
						Retrieved from "<a dir="ltr" href="https://en.wikipedia.org/w/index.php?title=Hairy_cell_leukemia&amp;oldid=665127407">https://en.wikipedia.org/w/index.php?title=Hairy_cell_leukemia&amp;oldid=665127407</a>"					</div>
				<div id='catlinks' class='catlinks'><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/wiki/Help:Category" title="Help:Category">Categories</a>: <ul><li><a href="/wiki/Category:Lymphocytic_leukemia" title="Category:Lymphocytic leukemia">Lymphocytic leukemia</a></li><li><a href="/wiki/Category:Lymphoid-related_cutaneous_conditions" title="Category:Lymphoid-related cutaneous conditions">Lymphoid-related cutaneous conditions</a></li></ul></div><div id="mw-hidden-catlinks" class="mw-hidden-catlinks mw-hidden-cats-hidden">Hidden categories: <ul><li><a href="/wiki/Category:Pages_with_DOIs_inactive_since_2015" title="Category:Pages with DOIs inactive since 2015">Pages with DOIs inactive since 2015</a></li><li><a href="/wiki/Category:CS1_Japanese-language_sources_(ja)" title="Category:CS1 Japanese-language sources (ja)">CS1 Japanese-language sources (ja)</a></li><li><a href="/wiki/Category:Articles_with_contributors_link" title="Category:Articles with contributors link">Articles with contributors link</a></li><li><a href="/wiki/Category:Articles_that_use_a_Medicine_navs_subtemplate" title="Category:Articles that use a Medicine navs subtemplate">Articles that use a Medicine navs subtemplate</a></li></ul></div></div>				<div class="visualClear"></div>
							</div>
		</div>
		<div id="mw-navigation">
			<h2>Navigation menu</h2>

			<div id="mw-head">
									<div id="p-personal" role="navigation" class="" aria-labelledby="p-personal-label">
						<h3 id="p-personal-label">Personal tools</h3>
						<ul>
							<li id="pt-createaccount"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Hairy+cell+leukemia&amp;type=signup" title="You are encouraged to create an account and log in; however, it is not mandatory">Create account</a></li><li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Hairy+cell+leukemia" title="You're encouraged to log in; however, it's not mandatory. [o]" accesskey="o">Log in</a></li>						</ul>
					</div>
									<div id="left-navigation">
										<div id="p-namespaces" role="navigation" class="vectorTabs" aria-labelledby="p-namespaces-label">
						<h3 id="p-namespaces-label">Namespaces</h3>
						<ul>
															<li  id="ca-nstab-main" class="selected"><span><a href="/wiki/Hairy_cell_leukemia"  title="View the content page [c]" accesskey="c">Article</a></span></li>
															<li  id="ca-talk"><span><a href="/wiki/Talk:Hairy_cell_leukemia"  title="Discussion about the content page [t]" accesskey="t" rel="discussion">Talk</a></span></li>
													</ul>
					</div>
										<div id="p-variants" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-variants-label">
												<h3 id="p-variants-label">
							<span>Variants</span><a href="#"></a>
						</h3>

						<div class="menu">
							<ul>
															</ul>
						</div>
					</div>
									</div>
				<div id="right-navigation">
										<div id="p-views" role="navigation" class="vectorTabs" aria-labelledby="p-views-label">
						<h3 id="p-views-label">Views</h3>
						<ul>
															<li id="ca-view" class="selected"><span><a href="/wiki/Hairy_cell_leukemia" >Read</a></span></li>
															<li id="ca-edit"><span><a href="/w/index.php?title=Hairy_cell_leukemia&amp;action=edit"  title="Edit this page [e]" accesskey="e">Edit</a></span></li>
															<li id="ca-history" class="collapsible"><span><a href="/w/index.php?title=Hairy_cell_leukemia&amp;action=history"  title="Past versions of this page [h]" accesskey="h">View history</a></span></li>
													</ul>
					</div>
										<div id="p-cactions" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-cactions-label">
						<h3 id="p-cactions-label"><span>More</span><a href="#"></a></h3>

						<div class="menu">
							<ul>
															</ul>
						</div>
					</div>
										<div id="p-search" role="search">
						<h3>
							<label for="searchInput">Search</label>
						</h3>

						<form action="/w/index.php" id="searchform">
							<div id="simpleSearch">
							<input type="search" name="search" placeholder="Search" title="Search Wikipedia [f]" accesskey="f" id="searchInput" /><input type="hidden" value="Special:Search" name="title" /><input type="submit" name="fulltext" value="Search" title="Search Wikipedia for this text" id="mw-searchButton" class="searchButton mw-fallbackSearchButton" /><input type="submit" name="go" value="Go" title="Go to a page with this exact name if one exists" id="searchButton" class="searchButton" />							</div>
						</form>
					</div>
									</div>
			</div>
			<div id="mw-panel">
				<div id="p-logo" role="banner"><a class="mw-wiki-logo" href="/wiki/Main_Page"  title="Visit the main page"></a></div>
						<div class="portal" role="navigation" id='p-navigation' aria-labelledby='p-navigation-label'>
			<h3 id='p-navigation-label'>Navigation</h3>

			<div class="body">
									<ul>
						<li id="n-mainpage-description"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z">Main page</a></li><li id="n-contents"><a href="/wiki/Portal:Contents" title="Guides to browsing Wikipedia">Contents</a></li><li id="n-featuredcontent"><a href="/wiki/Portal:Featured_content" title="Featured content – the best of Wikipedia">Featured content</a></li><li id="n-currentevents"><a href="/wiki/Portal:Current_events" title="Find background information on current events">Current events</a></li><li id="n-randompage"><a href="/wiki/Special:Random" title="Load a random article [x]" accesskey="x">Random article</a></li><li id="n-sitesupport"><a href="https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&amp;utm_medium=sidebar&amp;utm_campaign=C13_en.wikipedia.org&amp;uselang=en" title="Support us">Donate to Wikipedia</a></li><li id="n-shoplink"><a href="//shop.wikimedia.org" title="Visit the Wikimedia Shop">Wikipedia store</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-interaction' aria-labelledby='p-interaction-label'>
			<h3 id='p-interaction-label'>Interaction</h3>

			<div class="body">
									<ul>
						<li id="n-help"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia">Help</a></li><li id="n-aboutsite"><a href="/wiki/Wikipedia:About" title="Find out about Wikipedia">About Wikipedia</a></li><li id="n-portal"><a href="/wiki/Wikipedia:Community_portal" title="About the project, what you can do, where to find things">Community portal</a></li><li id="n-recentchanges"><a href="/wiki/Special:RecentChanges" title="A list of recent changes in the wiki [r]" accesskey="r">Recent changes</a></li><li id="n-contactpage"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact page</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-tb' aria-labelledby='p-tb-label'>
			<h3 id='p-tb-label'>Tools</h3>

			<div class="body">
									<ul>
						<li id="t-whatlinkshere"><a href="/wiki/Special:WhatLinksHere/Hairy_cell_leukemia" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j">What links here</a></li><li id="t-recentchangeslinked"><a href="/wiki/Special:RecentChangesLinked/Hairy_cell_leukemia" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</a></li><li id="t-upload"><a href="/wiki/Wikipedia:File_Upload_Wizard" title="Upload files [u]" accesskey="u">Upload file</a></li><li id="t-specialpages"><a href="/wiki/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q">Special pages</a></li><li id="t-permalink"><a href="/w/index.php?title=Hairy_cell_leukemia&amp;oldid=665127407" title="Permanent link to this revision of the page">Permanent link</a></li><li id="t-info"><a href="/w/index.php?title=Hairy_cell_leukemia&amp;action=info" title="More information about this page">Page information</a></li><li id="t-wikibase"><a href="//www.wikidata.org/wiki/Q201299" title="Link to connected data repository item [g]" accesskey="g">Wikidata item</a></li><li id="t-cite"><a href="/w/index.php?title=Special:CiteThisPage&amp;page=Hairy_cell_leukemia&amp;id=665127407" title="Information on how to cite this page">Cite this page</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-coll-print_export' aria-labelledby='p-coll-print_export-label'>
			<h3 id='p-coll-print_export-label'>Print/export</h3>

			<div class="body">
									<ul>
						<li id="coll-create_a_book"><a href="/w/index.php?title=Special:Book&amp;bookcmd=book_creator&amp;referer=Hairy+cell+leukemia">Create a book</a></li><li id="coll-download-as-rdf2latex"><a href="/w/index.php?title=Special:Book&amp;bookcmd=render_article&amp;arttitle=Hairy+cell+leukemia&amp;oldid=665127407&amp;writer=rdf2latex">Download as PDF</a></li><li id="t-print"><a href="/w/index.php?title=Hairy_cell_leukemia&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-lang' aria-labelledby='p-lang-label'>
			<h3 id='p-lang-label'>Languages</h3>

			<div class="body">
									<ul>
						<li class="interlanguage-link interwiki-de"><a href="//de.wikipedia.org/wiki/Haarzellleuk%C3%A4mie" title="Haarzellleukämie – German" lang="de" hreflang="de">Deutsch</a></li><li class="interlanguage-link interwiki-es"><a href="//es.wikipedia.org/wiki/Tricoleucemia" title="Tricoleucemia – Spanish" lang="es" hreflang="es">Español</a></li><li class="interlanguage-link interwiki-fr"><a href="//fr.wikipedia.org/wiki/Leuc%C3%A9mie_%C3%A0_tricholeucocytes" title="Leucémie à tricholeucocytes – French" lang="fr" hreflang="fr">Français</a></li><li class="interlanguage-link interwiki-gl"><a href="//gl.wikipedia.org/wiki/Tricoleucemia" title="Tricoleucemia – Galician" lang="gl" hreflang="gl">Galego</a></li><li class="interlanguage-link interwiki-it"><a href="//it.wikipedia.org/wiki/Tricoleucemia" title="Tricoleucemia – Italian" lang="it" hreflang="it">Italiano</a></li><li class="interlanguage-link interwiki-lt"><a href="//lt.wikipedia.org/wiki/Plaukuot%C5%B3j%C5%B3_l%C4%85steli%C5%B3_leukemija" title="Plaukuotųjų ląstelių leukemija – Lithuanian" lang="lt" hreflang="lt">Lietuvių</a></li><li class="interlanguage-link interwiki-nl"><a href="//nl.wikipedia.org/wiki/Haarcelleukemie" title="Haarcelleukemie – Dutch" lang="nl" hreflang="nl">Nederlands</a></li><li class="interlanguage-link interwiki-pl"><a href="//pl.wikipedia.org/wiki/Bia%C5%82aczka_w%C5%82ochatokom%C3%B3rkowa" title="Białaczka włochatokomórkowa – Polish" lang="pl" hreflang="pl">Polski</a></li><li class="interlanguage-link interwiki-pt"><a href="//pt.wikipedia.org/wiki/Tricoleucemia" title="Tricoleucemia – Portuguese" lang="pt" hreflang="pt">Português</a></li><li class="interlanguage-link interwiki-fi"><a href="//fi.wikipedia.org/wiki/Karvasoluleukemia" title="Karvasoluleukemia – Finnish" lang="fi" hreflang="fi">Suomi</a></li><li class="interlanguage-link interwiki-sv"><a href="//sv.wikipedia.org/wiki/H%C3%A5rcellsleukemi" title="Hårcellsleukemi – Swedish" lang="sv" hreflang="sv">Svenska</a></li><li class="uls-p-lang-dummy"><a href="#"></a></li>					</ul>
				<div class='after-portlet after-portlet-lang'><span class="wb-langlinks-edit wb-langlinks-link"><a href="//www.wikidata.org/wiki/Q201299#sitelinks-wikipedia" title="Edit interlanguage links" class="wbc-editpage">Edit links</a></span></div>			</div>
		</div>
				</div>
		</div>
		<div id="footer" role="contentinfo">
							<ul id="footer-info">
											<li id="footer-info-lastmod"> This page was last modified on 2 June 2015, at 05:27.</li>
											<li id="footer-info-copyright">Text is available under the <a rel="license" href="//en.wikipedia.org/wiki/Wikipedia:Text_of_Creative_Commons_Attribution-ShareAlike_3.0_Unported_License">Creative Commons Attribution-ShareAlike License</a><a rel="license" href="//creativecommons.org/licenses/by-sa/3.0/" style="display:none;"></a>;
additional terms may apply.  By using this site, you agree to the <a href="//wikimediafoundation.org/wiki/Terms_of_Use">Terms of Use</a> and <a href="//wikimediafoundation.org/wiki/Privacy_policy">Privacy Policy</a>. Wikipedia® is a registered trademark of the <a href="//www.wikimediafoundation.org/">Wikimedia Foundation, Inc.</a>, a non-profit organization.</li>
									</ul>
							<ul id="footer-places">
											<li id="footer-places-privacy"><a href="//wikimediafoundation.org/wiki/Privacy_policy" title="wikimedia:Privacy policy">Privacy policy</a></li>
											<li id="footer-places-about"><a href="/wiki/Wikipedia:About" title="Wikipedia:About">About Wikipedia</a></li>
											<li id="footer-places-disclaimer"><a href="/wiki/Wikipedia:General_disclaimer" title="Wikipedia:General disclaimer">Disclaimers</a></li>
											<li id="footer-places-contact"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact Wikipedia</a></li>
											<li id="footer-places-developers"><a href="https://www.mediawiki.org/wiki/Special:MyLanguage/How_to_contribute">Developers</a></li>
											<li id="footer-places-mobileview"><a href="//en.m.wikipedia.org/w/index.php?title=Hairy_cell_leukemia&amp;mobileaction=toggle_view_mobile" class="noprint stopMobileRedirectToggle">Mobile view</a></li>
									</ul>
										<ul id="footer-icons" class="noprint">
											<li id="footer-copyrightico">
							<a href="//wikimediafoundation.org/"><img src="/static/images/wikimedia-button.png" srcset="/static/images/wikimedia-button-1.5x.png 1.5x, /static/images/wikimedia-button-2x.png 2x" width="88" height="31" alt="Wikimedia Foundation"/></a>						</li>
											<li id="footer-poweredbyico">
							<a href="//www.mediawiki.org/"><img src="//en.wikipedia.org/static/1.26wmf13/resources/assets/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="//en.wikipedia.org/static/1.26wmf13/resources/assets/poweredby_mediawiki_132x47.png 1.5x, //en.wikipedia.org/static/1.26wmf13/resources/assets/poweredby_mediawiki_176x62.png 2x" width="88" height="31" /></a>						</li>
									</ul>
						<div style="clear:both"></div>
		</div>
		<script>if(window.jQuery)jQuery.ready();</script><script>if(window.mw){
mw.loader.state({"ext.globalCssJs.site":"ready","ext.globalCssJs.user":"ready","site":"loading","user":"ready","user.groups":"ready"});
}</script>
<link rel="stylesheet" href="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=ext.cite.styles%7Cext.gadget.DRN-wizard%2CReferenceTooltips%2CWatchlistGreenIndicators%2Ccharinsert%2Cfeatured-articles-links%2CrefToolbar%2Cswitcher%2Cteahouse%7Cext.wikimediaBadges&amp;only=styles&amp;skin=vector&amp;*" />
<script>if(window.mw){
mw.loader.load(["ext.cite.a11y","mediawiki.toc","mediawiki.action.view.postEdit","mediawiki.user","mediawiki.hidpi","mediawiki.page.ready","mediawiki.searchSuggest","ext.cirrusSearch.loggingSchema","mmv.bootstrap.autostart","ext.imageMetrics.loader","ext.eventLogging.subscriber","ext.wikimediaEvents","ext.wikimediaEvents.statsd","ext.navigationTiming","ext.gadget.teahouse","ext.gadget.ReferenceTooltips","ext.gadget.WatchlistGreenIndicators","ext.gadget.DRN-wizard","ext.gadget.charinsert","ext.gadget.refToolbar","ext.gadget.switcher","ext.gadget.featured-articles-links","ext.visualEditor.targetLoader","schema.UniversalLanguageSelector","ext.uls.eventlogger","ext.uls.interlanguage"],null,true);
}</script>
<script>if(window.mw){
document.write("\u003Cscript src=\"//en.wikipedia.org/w/load.php?debug=false\u0026amp;lang=en\u0026amp;modules=site\u0026amp;only=scripts\u0026amp;skin=vector\u0026amp;*\"\u003E\u003C/script\u003E");
}</script>
<script>if(window.mw){
mw.config.set({"wgBackendResponseTime":104,"wgHostname":"mw1035"});
}</script>
	</body>
</html>
